22nd Century (XXII) 10-K1 Mar 222021 FY Annual reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2021	Feb. 22, 2022	Jun. 30, 2021
Document and Entity Information
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity File Number	001-36338
Entity Registrant Name	22nd Century Group, Inc.
Entity Central Index Key	0001347858
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	98-0468420
Entity Address, Address Line One	500 Seneca Street, Suite 507
Entity Address, City or Town	Buffalo
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14204
City Area Code	716
Local Phone Number	270-1523
Title of 12(b) Security	Common Stock, $0.00001 par value
Security Exchange Name	NASDAQ
Trading Symbol	XXII
Entity Current Reporting Status	Yes
ICFR Auditor Attestation Flag	true
Auditor Name	Freed Maxick, CPAs, P.C.
Auditor Firm ID	317
Auditor Location	Buffalo, New York
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 740
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		162,938,375

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 1,336	$ 1,029
Short-term investment securities	47,400	21,313
Accounts receivable, net	585	2,159
Inventory, net	2,881	2,034
Prepaid expenses and other assets	2,183	1,806
Total current assets	54,385	28,341
Property, plant and equipment, net	5,841	2,483
Operating leases right-of-use assets, net	1,723	247
Intangible assets, net	7,919	8,211
Investments	2,345	6,536
Other assets	3,741	5,876
Total assets	75,954	51,694
Current liabilities:
Notes payable	596	539
Operating lease obligations	308	247
Accounts payable	2,173	1,116
Accrued expenses	1,489	931
Accrued payroll	2,255	2,208
Accrued excise taxes and fees	1,270	1,691
Accrued severance	217	339
Deferred income	119	272
Total current liabilities	8,427	7,343
Long-term liabilities:
Operating lease obligations	1,432
Severance obligations	21	241
Total liabilities	9,880	7,584
Commitments and contingencies (Note 12)
Shareholders' equity
Preferred stock, $.00001 par value, 10,000,000 shares authorized
Common stock, par value	2	1
Capital in excess of par value	244,247	189,439
Accumulated other comprehensive (loss) income	(162)	74
Accumulated deficit	(178,013)	(145,404)
Total shareholders' equity	66,074	44,110
Total liabilities and shareholders' equity	$ 75,954	$ 51,694

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
CONSOLIDATED BALANCE SHEETS
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares issued	162,872,875	139,061,690
Common stock, shares outstanding	162,872,875	139,061,690

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Sale of products, net	$ 30,948	$ 28,111	$ 25,833
Cost of goods sold (exclusive of depreciation shown separately below):
Products	28,879	26,673	25,818
Gross profit (loss)	2,069	1,438	15
Operating expenses:
Sales, general and administrative	25,881	14,971	12,954
Impairment of intangible assets	78	176	1,142
Depreciation	633	688	589
Amortization	615	658	836
Total operating expenses	30,481	20,621	23,581
Operating loss	(28,412)	(19,183)	(23,566)
Other income (expense):
Unrealized gain (loss) on investments	(6,994)	(434)	(2,419)
Impairment of Panacea investment		(1,741)
Gain on Panacea investment conversion	2,548
Realized gain (loss) on short-term investment securities		5	221
Litigation settlement			(1,891)
Gain on the sale of property, plant and equipment		1	87
Interest income, net	321	1,751	1,066
Interest expense	(58)	(72)	(56)
Total other income (expense)	(4,183)	(490)	(2,992)
Loss before income taxes	(32,595)	(19,673)	(26,558)
Income taxes	14	38
Net loss	(32,609)	(19,711)	(26,558)
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investment securities	(236)	72	207
Reclassification of (gain) loss to net loss		(5)	(221)
Other comprehensive income (loss)	(236)	67	(14)
Comprehensive loss	$ (32,845)	$ (19,644)	$ (26,572)
Net loss per common share - basic	$ (0.21)	$ (0.14)	$ (0.21)
Net loss per common share - diluted	$ (0.21)	$ (0.14)	$ (0.21)
Weighted average common shares outstanding - basic	156,208	138,813	125,883
Weighted average common shares outstanding - diluted	156,208	138,813	125,883
Products Other Than Modified Risk Tobacco Products [Member]
Operating expenses:
Research and development	$ 3,256	$ 4,090	$ 6,381
Modified Risk Tobacco Product [Member]
Operating expenses:
Research and development	$ 18	$ 38	$ 1,679

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Capital in Excess of Par Value	Other Comprehensive Income Loss	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2018	$ 1	$ 170,391	$ 21	$ (99,135)	$ 71,278
Beginning balance (in shares) at Dec. 31, 2018	124,642,593
Stock issued in connection with RSU vesting (in shares)	100,000
Stock issued in connection with warrant exercises		10,616			$ 10,616
Stock issued in connection with warrant exercises (in shares)	11,293,211
Stock issued in connection with option exercises (in shares)	39,988				75,000
Equity-based compensation		3,540			$ 3,540
Stock issued in connection with litigation expense		1,891			1,891
Stock issued in connection with litigation expense (in shares)	990,000
Stock issued in connection with Panacea investment		1,297			1,297
Stock issued in connection with Panacea investment (in shares)	1,297,017
Unrealized gain (loss) on short-term investment securities			207		207
Reclassification of losses (gains) to net loss			(221)		(221)
Net loss				(26,558)	(26,558)
Ending balance at Dec. 31, 2019	$ 1	187,735	7	(125,693)	62,050
Ending balance (in shares) at Dec. 31, 2019	138,362,809
Stock issued in connection with RSU vesting (in shares)	552,800
Stock issued in connection with option exercises		50			$ 50
Stock issued in connection with option exercises (in shares)	146,081				399,000
Equity-based compensation		1,654			$ 1,654
Unrealized gain (loss) on short-term investment securities			72		72
Reclassification of losses (gains) to net loss			(5)		(5)
Net loss				(19,711)	(19,711)
Ending balance at Dec. 31, 2020	$ 1	189,439	74	(145,404)	44,110
Ending balance (in shares) at Dec. 31, 2020	139,061,690
Stock issued in connection with RSU vesting, net of shares withheld for taxes		(469)			(469)
Stock issued in connection with RSU vesting, net of shares withheld for taxes (in shares)	1,534,361
Stock issued in connection with warrant exercises	$ 1	11,781			11,782
Stock issued in connection with warrant exercises (in shares)	11,293,211
Stock issued in connection with option exercises		1,307			$ 1,307
Stock issued in connection with option exercises (in shares)	983,613				984,000
Stock issued in connection with capital raise		38,206			$ 38,206
Stock issued in connection with capital raise (in shares)	10,000,000
Equity-based compensation		3,983			3,983
Unrealized gain (loss) on short-term investment securities			(236)		(236)
Net loss				(32,609)	(32,609)
Ending balance at Dec. 31, 2021	$ 2	$ 244,247	$ (162)	$ (178,013)	$ 66,074
Ending balance (in shares) at Dec. 31, 2021	162,872,875

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (32,609)	$ (19,711)	$ (26,558)
Adjustments to reconcile net loss to cash used in operating activities:
Impairment of intangible assets	78	176	1,142
Impairment of Panacea investment		1,741
Amortization and depreciation	999	1,094	1,186
Amortization of license fees	249	251	239
Amortization of ROU assets	288	182	212
Unrealized (gain) loss on investment	6,994	434	2,419
Realized (gain) loss on short-term investment securities		(5)	(221)
Litigation settlement			1,891
Gain on the sale of machinery and equipment		(1)	(87)
Gain on Panacea investment conversion	(2,548)
Accretion of non-cash interest expense (income)	143	(326)	26
Equity-based employee compensation expense	3,983	1,654	3,540
Inventory write-off	317	521	985
(Increase) decrease in assets:
Accounts receivable	1,574	(1,292)	4
Inventory	(1,164)	(289)	(207)
Prepaid expenses and other assets	(547)	(787)	280
Increase (decrease) in liabilities:
Operating lease obligations	(272)	(552)	(212)
Accounts payable	11	(936)	(732)
Accrued expenses	533	499	243
Accrued payroll	47	1,121	498
Accrued excise taxes and fees	(421)	563	51
Accrued severance	(341)	(225)	792
Deferred income	(153)	267	(78)
Net cash provided by (used in) operating activities	(22,839)	(15,621)	(14,588)
Cash flows from investing activities:
Acquisition of patents, trademarks, and licenses	(326)	(468)	(565)
Acquisition of property, plant and equipment	(745)	(54)	(527)
Proceeds from the sale of machinery and equipment		6	166
Investment in Panacea			(12,000)
Sales and maturities of short-term investment securities	63,749	39,728	19,320
Purchase of short-term investment securities	(90,407)	(22,743)	(1,842)
Net cash provided by (used in) investing activities	(27,729)	16,469	4,552
Cash flows from financing activities:
Payment on note payable	(2,604)	(2,549)	(700)
Proceeds from note payable issuance	2,653	2,195
Net proceeds from option exercises	1,307	50
Net proceeds from warrant exercises	11,782		10,616
Net proceeds from issuance of common stock	38,206
Taxes paid related to net share settlement of RSUs	(469)
Proceeds from SBA loan		1,183
Repayment of SBA loan		(1,183)
Net cash provided by (used in) financing activities	50,875	(304)	9,916
Net increase (decrease) in cash and cash equivalents	307	544	(120)
Cash and cash equivalents - beginning of period	1,029	485	605
Cash and cash equivalents - end of period	1,336	1,029	485
Net cash paid for:
Cash paid during the period for interest	37	29	3
Non-cash transactions:
Patent and trademark additions included in accounts payable	51	55	155
Property, plant and equipment additions included in accounts payable	998	2
Right-of-use assets and corresponding operating lease obligations	1,816	198	814
Patent and trademark additions included in accrued expenses	25	$ 28
Stock issued in connection with investment			$ 1,297
Panacea investment conversion	$ 12,485

NATURE OF BUSINESS AND SUMMARY

NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2021
NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. – NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation Nature of Business COVID-19 Pandemic Preferred stock authorized Foreign currency translation– Concentration of Credit Risk Cash and cash equivalents – Short-term investment securities securities, and commercial paper with maturities greater than three months at the time of acquisition. The Company’s short-term investment securities are carried at fair value within current assets on the Company’s Consolidated Balance Sheets. The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security. The Company’s investment policy states that all investment securities must have a maximum maturity of twenty-four Accounts receivable Inventory Property, plant and equipment – Intangible Assets The Company’s capitalized intellectual property costs are amortized using the straight-line method over the remaining statutory life of the patent assets in each of the Company’s patent families, which have estimated expiration dates ranging from 2026 to 2042. Periodic maintenance or renewal fees are expensed as incurred. Annual minimum license fees are charged to expense. License fees paid for third-party intellectual property are amortized on a straight-line basis over the last to expire patents, which have expected expiration dates from 2028 through 2036. The Company believes that costs associated with becoming a signatory to the MSA, costs related to the acquisition of a predicate cigarette brand and trademarks have indefinite lives. As such, no amortization is taken. At each reporting period, the Company evaluates whether events and circumstances continue to support the indefinite-lived classification. Impairment of Long-Lived Assets Property, plant, and equipment Intangibles, Goodwill, and Other Intangible assets subject to amortization are reviewed for strategic importance and commercialization opportunity prior to expiration. If it is determined that the asset no longer supports the Company’s strategic objectives and/or will not be commercially viable prior to expiration, the asset is impaired. In addition, the Company will assess the expected future undiscounted cash flows for its intellectual property based on consideration of future market and economic conditions, competition, federal and state regulations, and licensing opportunities. If the carrying value of such assets are not recoverable, the carrying value will be reduced to fair value and record the difference as an impairment. Indefinite-lived intangible asset carrying values are reviewed at least annually or more frequently if events or changes in circumstances indicate that it is more likely than not that an impairment exists. The Company first performs a qualitative assessment and considers its current strategic objectives, future market and economic conditions, competition, and federal and state regulations to determine if an impairment is more likely than not. If it is determined that an impairment is more likely than not, a quantitative assessment is performed to compare the asset carrying value to fair value. Right-of-use (“ROU”) assets and Lease Obligations Refer to Note 4 for additional information regarding our ROU assets and liabilities. Income Taxes As a result of the Company’s history of cumulative net operating losses and the uncertainty of their future utilization, the Company has established a valuation allowance to fully offset its net deferred tax assets as of December 31, 2021 and December 31, 2020. Additionally, the Company has elected to present other comprehensive income items relating to net unrealized gains on short-term investment securities gross and not net of taxes. The Company’s federal and state tax returns for the years ended December 31, 2018 through December 31, 2020 are currently open to audit under the statutes of limitations. There are no pending audits as of December 31, 2021. Stock Based Compensation Revenue Recognition Derivatives Research and Development Loss Per Common Share Use of Estimates Fair Value of Financial Instruments Investments Loss Contingencies Recent Accounting Pronouncement(s) – In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments.” The standard replaces the incurred loss model with the current expected credit loss (CECL) model to estimate credit losses for financial assets measured at amortized cost and certain off-balance sheet credit exposures. The CECL model requires companies to estimate credit losses expected over the life of the financial assets based on historical experience, current conditions and reasonable and supportable forecasts. The provisions of the ASU are effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years—excluding small reporting companies (SRCs), based on a determination date as of November 15, 2019, which have an effective date beginning after December 15, 2022 and interim periods within those fiscal years. The Company is evaluating the expected impacts of the ASU. We consider the applicability and impact of all ASUs. If the ASU is not listed above, it was determined that the ASU was either not applicable or would have an immaterial impact on our financial statements and related disclosures. .

INVENTORY

INVENTORY	12 Months Ended
INVENTORY	Dec. 31, 2021
INVENTORY
INVENTORY	NOTE 2. – INVENTORY Inventories at December 31, 2021 and December 31, 2020 consisted of the following: December 31, December 31, 2021 2020 Inventory - tobacco leaf $ 1,352 $ 821 Inventory - hemp/cannabis 10 — Inventory - finished goods Cigarettes and filtered cigars 256 171 Inventory - raw materials Cigarette and filtered cigar components 1,363 1,142 Less: inventory reserve (100) (100) $ 2,881 $ 2,034 During the year ended December 31, 2021, the Company wrote off inventory totaling $317 which is included within costs of goods sold on the Company’s Consolidated Statement of Operations and Comprehensive Loss. During the year ended December 31, 2020, the Company wrote off inventory totaling $521 on the Company’s Consolidated Statement of Operations and Comprehensive Loss ( $361 included within research and development expenses and $161 included within cost of goods sold.)

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	12 Months Ended
PROPERTY, PLANT AND EQUIPMENT, NET	Dec. 31, 2021
PROPERTY, PLANT AND EQUIPMENT, NET
PROPERTY, PLANT AND EQUIPMENT, NET	NOTE 3. – PROPERTY, PLANT AND EQUIPMENT, NET Property, plant and equipment, net at December 31, 2021 and December 31, 2020 consisted of the following: December 31, December 31, Useful Life 2021 2020 Land $ 1,665 $ — Building and leasehold improvements 7 309 123 Manufacturing equipment 3 5,541 4,893 Office furniture, fixtures and equipment 3 139 20 Laboratory equipment 5 years 198 117 Construction in progress 1,289 — Less: accumulated depreciation (3,300) (2,670) Property, plant and equipment, net $ 5,841 $ 2,483 Depreciation expense was $633, $688, and $589 for the years ended December 31, 2021, 2020 and 2019, respectively.

RIGHT-OF-USE ASSETS, LEASE OBLI

RIGHT-OF-USE ASSETS, LEASE OBLIGATIONS, AND OTHER LEASES	12 Months Ended
RIGHT-OF-USE ASSETS, LEASE OBLIGATIONS, AND OTHER LEASES	Dec. 31, 2021
RIGHT-OF-USE ASSETS, LEASE OBLIGATIONS, AND OTHER LEASES
RIGHT-OF-USE ASSETS, LEASE OBLIGATIONS, AND OTHER LEASES	NOTE 4. – RIGHT-OF-USE ASSETS, LEASE OBLIGATIONS, AND OTHER LEASES The Company leases a manufacturing facility and warehouse in North Carolina, a corporate headquarters in Buffalo, New York, and a laboratory space in Rockville, Maryland. During the fourth quarter of 2020, the Company made the decision to not renew its corporate headquarters lease in Williamsville, NY which had an initial term expiring on January 1, 2021. Upon adoption of ASC 842-Leases, the Company assumed all three optional one-year renewal options which created a lease term expiration inclusive of all initial renewal options within the lease agreement—which assumed a lease term expiration in 2023. With the non-renewal decision, the Company’s lease operated on a month-to-month basis beginning on January 1, 2021. As such, the ROU asset and lease obligation was removed from the Consolidated Balance Sheets as of December 31, 2020. On January 15, 2021, the Company signed a lease agreement to relocate its corporate headquarters to the Larkinville District in downtown Buffalo, New York. The Company moved into the new office location in April 2021 and signed an amended lease agreement which revised the original lease commencement date to April 1, 2021. The lease has a monthly base rent of $6 , which escalates 2.5% annually after the first year, and an initial term of 36 months —with two twenty-four-month optional renewal options at the Company’s discretion. On July 28, 2021, the Company signed a lease agreement for a new research and development (“R&D”) laboratory in Rockville, MD. The new laboratory space has over four thousand square feet and will support the Company’s continued growth and R&D partnerships. The lease has an initial monthly base rent of $12 (escalating 2.5% annually after the first year), a term of 51 months, and commenced on December 1, 2021. The lease also calls for abatement of 100% of the base rent for the first five months following the lease commencement date. On October 18, 2021, the Company signed a lease extension for its manufacturing facility and warehouse in North Carolina. The lease commenced upon expiration of the previous lease term, which was November 1, 2021. The lease has a monthly base rent of $17 and an initial term of twenty-four months—with one twenty-four month renewal option at the Company’s discretion. The following table summarized the Company’s discount rate and remaining lease terms as of December 31, 2021: Weighted average remaining lease term in years 4.6 Weighted average discount rate 3.4 % Future minimum lease payments as of December 31, 2021 are as follows: 2022 373 2023 429 2024 448 2025 418 2026 111 Thereafter 108 Total lease payments 1,887 Less: imputed interest (147) Total $ 1,740 The Company also leases warehouse space in North Carolina and a small office space in Paoli, PA which do not fall under ASC 842 and are not included within our Consolidated Balance Sheets. Operating lease costs for the years ended December 31, 2021, 2020 and 2019, were $301, $335 and $250 respectively.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
INTANGIBLE ASSETS	Dec. 31, 2021
INTANGIBLE ASSETS
INTANGIBLE ASSETS	NOTE 5. – INTANGIBLE ASSETS Our intangible assets at December 31, 2021 and December 31, 2020 consisted of the following: December 31, December 31, 2021 2020 Intangible assets, net Patent and trademark costs $ 5,991 $ 5,667 Less: accumulated amortization (3,303) (2,936) Patent and trademark costs, net 2,688 2,731 License fees 3,876 3,876 Less: accumulated amortization (1,197) (948) License fees, net 2,679 2,928 MSA signatory costs 2,202 2,202 License fee for predicate cigarette brand 350 350 $ 7,919 $ 8,211 Amortization expense relating to the above intangible assets for the years ended December 31, 2021, 2020 and 2019 amounted to $615, $658, and $836, respectively. During the year ended December 31, 2021, the Company incurred a charge of $78 related to a write-down of our trademarks. During the years ended December 31, 2020 and 2019, the Company incurred an impairment related to patent intellectual property that either would be expired prior to expected commercialization or did not align to the Company’s strategic objectives. Impairment expense for the year ended December 31, 2020 and 2019, amounted to $176 (cost of approximately $448 less accumulated amortization of approximately $302) and $1,142 (cost of $2,092 less accumulated amortization of approximately $950), respectively. The impairment charges are included as a separate line item in operating expenses on the Company’s Consolidated Statements of Operations and Comprehensive Loss. The estimated annual average amortization expense patent costs license fees

INVESTMENTS & OTHER ASSETS

INVESTMENTS & OTHER ASSETS	12 Months Ended
INVESTMENTS & OTHER ASSETS	Dec. 31, 2021
INVESTMENTS & OTHER ASSETS
INVESTMENTS & OTHER ASSETS	NOTE 6. – INVESTMENTS & OTHER ASSETS Investment in Panacea Life Sciences, Inc. Initial Investment: On December 3, 2019, the Company entered into a securities purchase agreement with Panacea Life Sciences, Inc. (“Panacea”) for consideration valued at $13,297 ( $12,000 cash and $1,297 of the Company’s shares of common stock valued at $1 per share) in exchange for a 15.8% ownership interest. The Company’s investment consisted of three instruments: shares of Series B preferred stock (“preferred stock”); a convertible note receivable with a $7,000 face value; and a warrant (“stock warrant”) to purchase additional shares of Series B preferred stock, to obtain 51% ownership of Panacea, at an exercise price of $2.344 per share. The convertible note receivable had a term of five years , interest of 10% per annum, and could be converted to shares of Series B preferred stock at the Company’s discretion. The embedded conversion option was not considered a derivative instrument for accounting purposes. The preferred stock carried an annual 10% cumulative dividend, compounded annually, and had an implicit put option after the fifth anniversary date so long that the stock warrants had not been exercised. The put option was not considered a derivative instrument for accounting purposes. The stock warrant was exercisable at any time after the fifth anniversary date and would be accelerated if Panacea achieved certain sales targets for two consecutive years. The Series B preferred stock also included first priority equity preferences in the event of a liquidation, sale, or transfer of Panacea assets. These rights entitled the Company to the original Series B issuance price of $7,000 plus any unpaid accrued dividends. To allocate the cost of the stock warrant, the Company calculated a fair value based on the following assumptions: volatility of 70%, discount of 25% for lack of marketability, and a risk-free rate of 2%. The value of the stock warrant was allocated to the preferred stock and the convertible note receivable, equally, at a discount to the acquisition price. The discount on the preferred stock was determined to be for lack of control and the discount on the convertible note receivable was determined to be for issuing the note at a below market interest rate for similar instruments. The convertible note receivable and the preferred stock investment were considered available for sale debt securities with a private company that was not traded in active markets. Since observable price quotations were not available at acquisition, fair value was estimated based on cost less an appropriate discount upon acquisition. The discount of each instrument is accreted into interest income over the respective term as shown within the Company’s Consolidated Statements of Operations and Comprehensive Loss. See Note 7 for additional information on these fair value measurements. The stock warrant was recorded at its cost basis in accordance with the practicability exception under ASU 2016-01. Impairment of Panacea Investment: As a result of increased competition and other macroeconomic factors, the Company recognized an impairment of $1,062 on the Panacea stock warrant during the second quarter of 2020. The impairment is recorded within the Consolidated Statements of Operations and Comprehensive Loss as “Impairment of Panacea Investment.” During the fourth quarter of 2020, the Company entered into a non-binding agreement with Panacea to potentially restructure the investment and business relationship—including the transfer of an agricultural facility and other assets. As of December 31, 2020, the Company adjusted certain assets to represent the fair value outlined in the non-binding agreement. The Company’s non-binding agreement with Panacea to restructure the investment and business relationship generally provided for (i) the transfer of $7,170 in operational assets, including an agricultural facility and various extraction and distillation equipment, from Panacea to the Company in exchange for the cancellation of the $7,000 convertible note receivable plus accrued interest; (ii) an amendment of transaction documents to remove any future investment rights and obligations of the Company in Panacea, (iii) cancellation of the stock warrant to purchase additional Series B preferred stock; and (iv) various other amendments to Panacea’s charter to amend various investors rights therein. As a result of the expected outcome of this non-binding agreement, the Company determined that the carrying value of the stock warrant and the convertible note receivable plus accrued interest exceeded the fair value outlined in the non-binding agreement. As such, the Company recorded an impairment of $679, which reduced the stock warrant carrying value, so that the carrying value of the stock warrant, and convertible note receivable plus accrued interest amounted to a value of $7,170 as of December 31, 2020. The impairment is recorded within the Consolidated Statements of Operations and Comprehensive Loss as “Impairment of Panacea Investment.” In accordance with ASC 326- Financial Instruments-Credit Losses Conversion of Panacea Investment: On June 30, 2021, the Company entered into a Promissory Note Exchange Agreement with Panacea and a Securities Exchange Agreement with Panacea, Exactus, Inc. (“Exactus”) (OTCQB:EXDI) and certain other Panacea shareholders. Pursuant to the Securities Exchange Agreement, Exactus fully acquired Panacea. These transactions effected the (i) conversion of all of the Company’s Series B Preferred Stock in Panacea into 91,016,026 shares of common stock in Exactus valued at $9,102 as of June 30, 2021 and (ii) the conversion of the Company’s existing debt in Panacea by converting the outstanding $7,000 principal balance convertible note receivable and all accrued but unpaid interest thereon for fee simple ownership of Needle Rock Farms (224 acres in Delta County, Colorado) and equipment valued at $2,248, $500 in Panacea’s Series B Preferred Stock (which was subsequently converted to Exactus common stock under the Securities Exchange Agreement; this balance is reflected in final shares as stated above), and a new $4,300 promissory note (the “Promissory note receivable”) with a maturity date of June 30, 2026 and a 0% interest rate. The Promissory note receivable is with a related party of Panacea and is fully secured by a first priority lien on Panacea’s headquarters located in Golden, Colorado. All other rights and obligations of the Company in Panacea and Panacea’s affiliate, Quintel-MC Incorporated, were terminated by this transaction—including all warrant rights and obligations for future investment. The conversion was recorded as a non-monetary transaction, based on the fair value of the assets received, and resulted in a gain of $2,548 which is included within the Consolidated Statements of Operations and Comprehensive Loss as “Gain on Panacea investment conversion.” The Promissory note receivable was valued at $3,684 ($4,300 face value less $616 discount) and is included within the Consolidated Balance Sheets as “Other Assets.” The Company intends to hold the Promissory note receivable to maturity and the associated discount will be amortized into interest income over the term of the note. The ownership of Needle Rock Farms and related equipment is included within “Property, plant, and equipment, net” on the Consolidated Balance Sheets. The common shares of Exactus, Inc. are considered equity securities in accordance with ASC 321 and are recorded at fair value—changes in fair value will be included within the statement of operations. See Note 7 for additional information on the fair value measurements. On October 25, 2021, Exactus announced the completion of a 1 for 28 As of December 31, 2021, the total carrying value of the Company’s investment in Panacea is outlined below, net of 2020 impairment expense: December 31, December 31, 2021 2020 Panacea preferred stock $ — $ 5,173 Panacea stock warrant — 1,124 Accrued interest on convertible note receivable (included within prepaid expenses and other assets) — 170 Convertible note receivable — 5,876 Promissory note receivable 3,741 — Panacea Holdings common stock 2,340 — Total $ 6,082 $ 12,343 Investment in Aurora Cannabis, Inc. In 2018, in connection with the sale of its investment in a Canadian plant biotechnology company, the Company acquired stock warrants to purchase 973,971 common stock of Aurora Cannabis, Inc. (“Aurora”), a Canadian company (NYSE: ACB and TSX: ACB). The stock warrants have a five-year contractual term ending August 8, 2023 and had an exercise price of $9.37 Canadian Dollars (CAD) per share. During the second quarter of 2020, Aurora announced a 12 -to-1 reverse stock split which adjusted our total warrant to purchase 81,164 shares of Aurora common stock (from 973,971 ) at an exercise price of $112.44 CAD per share (from $9.37 CAD per share). The warrants are considered equity securities in accordance with ASC 321 – Investments – Equity Securities and a derivative instrument under ASC 815 – Derivatives and Hedging. The stock warrants are not designated as a hedging instrument, and in accordance with ASC 815, the Company’s investment in stock warrants are recorded at fair value with changes in fair value recorded to unrealized gain/loss as shown within the Company’s Consolidated Statements of Operations and Comprehensive Loss. See Note 7 for additional information on the fair value measurements. The carrying value of the Company’s investments at December 31, 2021 and December 31, 2020 consisted of the following: December 31, December 31, 2021 2020 Aurora stock warrants $ 5 $ 239 Panacea preferred stock — 5,173 Panacea stock warrant — 1,124 Panacea Holdings common stock 2,340 — Total Investments $ 2,345 $ 6,536 Convertible note receivable $ — $ 5,876 Promissory note receivable $ 3,741 $ —

FAIR VALUE MEASUREMENTS AND SHO

FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS	12 Months Ended
FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS	Dec. 31, 2021
FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS
FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS	NOTE 7. – FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS FASB ASC 820 - “Fair Value Measurements and Disclosures” establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: ● Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; ● Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and ● Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value. A financial asset’s or a financial liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The following table presents information about our assets and liabilities measured at fair value at December 31, 2021 and December 31, 2020, and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: Fair Value December 31, 2021 Level 1 Level 2 Level 3 Total Assets Short-term investment securities: Money market funds $ 8,919 $ — $ — $ 8,919 Corporate bonds — 38,481 — 38,481 Total short-term investment securities $ 8,919 $ 38,481 $ — $ 47,400 Investment - Aurora stock warrants $ — $ — $ 5 $ 5 Investment - Panacea Holdings common shares $ 2,340 $ — $ — $ 2,340 Fair Value December 31, 2020 Level 1 Level 2 Level 3 Total Assets Short-term investment securities: Money market funds $ 8,636 $ — $ — $ 8,636 Corporate bonds — 12,677 — 12,677 Total short-term investment securities $ 8,636 $ 12,677 $ — $ 21,313 Investment - Aurora stock warrants $ — $ — $ 239 $ 239 Investment - Panacea preferred stock $ — $ — $ 5,173 $ 5,173 Convertible note receivable $ — $ — $ 5,876 $ 5,876 Money market mutual funds are valued at their daily closing price as reported by the fund. Money market mutual funds held by the Company are open-end mutual funds that are registered with the SEC that generally transact at a stable $1.00 Net Asset Value (“NAV”) representing its estimated fair value. On a daily basis the fund’s NAV is determined by the fund based on the amortized cost of the funds underlying investments. Corporate bonds are valued using pricing models maximizing the use of observable inputs for similar securities. The investment in the Aurora stock warrants is measured at fair value using the Black-Scholes pricing model and is classified within Level 3 of the valuation hierarchy. The unobservable input is an estimated volatility factor of 92% and 137% as of December 31, 2021 and December 31, 2020, respectively. Therefore, changes in market volatility will impact the fair value measurement of our Aurora investment. A 20% increase or decrease in the volatility factor used as of December 31, 2021 would have the impact of increasing or decreasing the fair value measurement of the stock warrants by an average of approximately $6. A 20% increase or decrease in the volatility factor used at December 31, 2020 would have the impact of increasing or decreasing the fair value measurement of the stock warrants by an average of approximately $115. The investment in Panacea Holdings common shares is considered an equity security with a readily determinable fair value. The fair value is determined using the quotable market price as of the last trading day of the fiscal quarter. The Panacea convertible note receivable and the preferred stock investment are considered available-for-sale debt securities with a private company that is not traded in active markets. Since observable price quotations were not available, fair value was estimated based on cost less an appropriate discount upon acquisition. See Note 6 for further information regarding the Company’s investment in Panacea. The following table sets forth a summary of the changes in fair value of the Company’s Level 3 investments for the year ended December 31, 2021. Fair Value at December 31, 2019 $ 11,127 Unrealized loss as a result of change in fair value (434) Accretion of interest on Panacea investment 595 Fair Value at December 31, 2020 $ 11,288 Unrealized loss on Aurora stock warrants (233) Accretion of interest on Panacea preferred stock 142 Panacea investment conversion (11,192) Fair Value at December 31, 2021 $ 5 The following tables set forth a summary of the Company’s available-for-sale debt securities from amortized cost basis to fair value as of December 31, 2021 and December 31, 2020: Available for Sale Debt Securities December 31, 2021 Amortized Gross Gross Cost Unrealized Unrealized Fair Basis Gains Losses Value Corporate bonds $ 38,643 $ 1 $ (163) $ 38,481 Available for Sale Debt Securities December 31, 2020 Amortized Gross Gross Cost Unrealized Unrealized Fair Basis Gains Losses Value Corporate bonds $ 12,603 $ 74 $ — $ 12,677 Convertible note receivable 5,876 — — 5,876 Investment - Panacea preferred stock 5,173 — — 5,173 $ 23,652 $ 74 $ — $ 23,726 The following table sets forth a summary of the Company’s available-for-sale debt securities from amortized cost basis and fair value by contractual maturity as of December 31, 2021 and December 31, 2020: Available for Sale Debt Securities December 31, 2021 December 31, 2020 Amortized Amortized Cost Basis Fair Value Cost Basis Fair Value Due in one year or less $ 8,286 $ 8,280 $ 11,692 $ 11,753 Due after one year through five years 30,357 30,201 11,960 11,973 $ 38,643 $ 38,481 $ 23,652 $ 23,726

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
NOTES PAYABLE	Dec. 31, 2021
NOTES PAYABLE
NOTES PAYABLE	NOTE 8. – NOTES PAYABLE License Fees On June 22, 2018, the Company entered into the Second Amendment to the License Agreement (the “Second Amendment”) with North Carolina State University (“NCSU”) that amended an original License Agreement between the Company and NCSU, dated December 8, 2015, and the First Amendment, dated February 14, 2018, to the original License Agreement. Under the terms of the Second Amendment, the Company was obligated to pay NCSU milestone payments totaling $1,200, which originally amounted to a present value of $1,175. As of June 30, 2020, the Company paid the final milestone payment of $300. The cost of the of acquired license amounted to $1,175 and is included in Intangible assets, net on the Company’s Consolidated Balance Sheets, and is amortized on a straight-line basis over the last-to-expire patent, which is expected to be in 2036. On October 22, 2018, the Company entered into a License Agreement with the University of Kentucky. Under the terms of the License Agreement, the Company is obligated to pay the University of Kentucky milestone payments totaling $1,200, of which $300 was payable upon execution, and $300 will be payable annually over three years CARES Act Paycheck Protection Program Loan On May 1, 2020, the Company received a U.S. Small Business Administration Loan (“SBA Loan”) from Bank of America, N.A. related to the COVID-19 crisis in the amount of $1,200. On May 12, 2020, the Company repaid the SBA loan in full. D&O Insurance During the second quarter of 2021, the Company renewed its Director and Officer (“D&O”) insurance for a one-year policy premium totaling $3,315. The Company paid $662 as a premium down payment and financed the remaining $2,653 of policy premiums over nine months at a 3.49% annual percentage rate. During the second quarter of 2020, the Company renewed its D&O insurance for a one-year nine months The financed amount is recorded within current notes payable on the Company’s Consolidated Balance Sheets. The table below outlines our notes payable balances as of December 31, 2021 and December 31, 2020: December 31, December 31, 2021 2020 License Fees $ — $ 293 D&O Insurance 596 246 Total current notes payable $ 596 $ 539 Accretion of non-cash interest expense amounted to $7, $20, and $36 for the years ended December 31, 2021, 2020 and 2019, respectively.

SEVERANCE LIABILITY

SEVERANCE LIABILITY	12 Months Ended
SEVERANCE LIABILITY	Dec. 31, 2021
SEVERANCE LIABILITY
SEVERANCE LIABILITY	NOTE 9. – SEVERANCE LIABILITY During the second quarter of 2020, the Company recorded an accrual for severance benefits for $306 in accordance with FASB ASC 712 - “Compensation – Nonretirement Postemployment Benefits.” Consistent with certain contractual obligations related to a resignation, the Company will provide these severance benefits over a twelve-month period. During 2019, the Company recorded an accrual for severance benefits for $881 in accordance with FASB ASC 712 - “Compensation – Nonretirement Postemployment Benefits.” Consistent with certain contractual obligations, $771 of the related accrual will be paid via a monthly consulting fee for a period of forty-two months . The current and long-term accrued severance balance remaining as of December 31, 2021 was $217 and $21 , respectively. The current and long-term accrued severance balance remaining as of December 31, 2020 was $339 and $241 , respectively.

CAPITAL RAISE AND WARRANTS FOR

CAPITAL RAISE AND WARRANTS FOR COMMON STOCK	12 Months Ended
CAPITAL RAISE AND WARRANTS FOR COMMON STOCK	Dec. 31, 2021
CAPITAL RAISE AND WARRANTS FOR COMMON STOCK
CAPITAL RAISE AND WARRANTS FOR COMMON STOCK	NOTE 10. – CAPITAL RAISE AND WARRANTS FOR COMMON STOCK On June 7, 2021, the Company entered into a placement agent agreement (the “Placement Agent Agreement”) with Cowen and Company, LLC (the “Placement Agent”) relating to the Company’s registered direct offering (the “Offering”) to a select investor (the “Investor”). In addition, on June 7, 2021, the Company and the Investor entered into a securities purchase agreement relating to the issuance and sale of shares of common stock pursuant to which the Investor purchased 10,000,000 shares of common stock at $4.00 per share. The net proceeds to the Company from the Offering, after deducting Placement Agent fees and offering expenses, was $38,206. On November 25, 2019, the Company entered into Warrant Exercise Agreements (the "2019 Exercise Agreements") with all of the holders (the "Holders") of its outstanding warrants to purchase up to 11,293,211 shares of common stock of the Company with an exercise price of $2.15 per share (the "Warrants") whereby the Holders and the Company agreed that the Holders would immediately exercise for cash 7,350,000 of the Warrants at a reduced exercise price of $1.00 per share, generating proceeds to the Company before expenses of approximately $7,400. In addition, the Holders agreed to exercise the remaining 3,943,211 Warrants for cash on or prior to January 27, 2020 provided that the Holders are in compliance with the beneficial ownership limitation provisions contained in the Warrants. The Holders exercised all of the Warrants for cash during December 2019 and the Company received net proceeds of approximately $10,600 from the exercise of all of the Warrants, after deducting expenses associated with the transaction. In consideration for the Holders exercising their Warrants for cash, the Company issued to each Holder a new warrant (each, a "2019 Warrant") to purchase shares of common stock equal to the number of shares of common stock underlying the Warrants that shall be exercisable to the extent such Holder exercises for cash such Holder's Warrants pursuant to the 2019 Exercise Agreements. The terms of the 2019 warrants are (i) exercisable from first issuance of the 2019 Warrants for a period of five years and (ii) had an initial exercise price equal to $1.25 per share. On December 22, 2019, the Company entered in to a Warrant Amendment Agreement with the holders of the 2019 Warrants (the "Amendment") whereby the Company agreed to amend the Warrants to (i) reduce the exercise price of the Warrants to $1.11 and (ii) to add a call provision whereby the Company may call the Warrants with prior notice to the holders for $0.001 per Warrant (during which time the holders may exercise the Warrants) provided that the Company's volume weighted average stock price exceeds $3.00 per share for ten During the first quarter of 2021, the Company’s warrant holders exercised all 11,293,211 outstanding warrants for cash in exchange for common stock. In connection with these exercises, the Company received net proceeds of $11,782. No warrants remain outstanding as of December 31, 2021. The following table summarizes the Company’s warrant activity since December 31, 2018: Number of Warrants Warrants outstanding at December 31, 2018 11,293,211 Exercised (11,293,211) Issued 11,293,211 Warrants outstanding at December 31, 2019 11,293,211 Exercised — Issued — Warrants outstanding at December 31, 2020 11,293,211 Exercised (11,293,211) Issued — Warrants outstanding at December 31, 2021 —

RETIREMENT PLAN

RETIREMENT PLAN	12 Months Ended
RETIREMENT PLAN	Dec. 31, 2021
RETIREMENT PLAN
RETIREMENT PLAN	NOTE 11. – RETIREMENT PLAN The Company sponsors a defined contribution plan under IRC Section 401(k). The plan covers all employees who meet the minimum eligibility requirements. Under the 401(k) plan eligible employees are allowed to make voluntary deferred salary contribution to the plan, subject to statutory limits. The Company has elected to make Safe Harbor Non-Elective Contributions to the plan for eligible employees in the amount of three percent (3%) of the employee’s compensation. Total employer contributions to the plan for the years ended December 31, 2021, 2020 and 2019 amounted to $171, $150 and $157, respectively.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Dec. 31, 2021
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 12. – COMMITMENTS AND CONTINGENCIES License agreements and sponsored research – Future Commitments Commitment Counter Party Product Relationship Commitment Type 2022 2023 2024 2025 2026 & After Total Research Agreement KeyGene Hemp / Cannabis Contract fee $ 1,150 $ 1,200 $ 1,227 $ 1,264 $ 1,630 $ 6,471 (1) License Agreement NCSU Tobacco Annual royalty fee 225 — — — — 225 (2), (3) License Agreement NCSU Tobacco Minimum annual royalty 50 50 50 50 550 750 (2) License Agreement NCSU Tobacco Minimum annual royalty 50 50 50 50 450 650 (2) Sublicense Agreement Anandia Laboratories, Inc. Hemp / Cannabis Annual license fee 10 10 10 10 100 140 (3) Growing Agreements Various Various Contract fee 38 — — — — 38 (4) Consulting Agreements Various Various Contract fee 1,370 808 — — — 2,178 (5) $ 2,893 $ 2,118 $ 1,337 $ 1,374 $ 2,730 $ 10,452 (1) Exclusive agreement with the Company with respect to the Cannabis Sativa L. plant (the "Field"). The initial term of the agreement was five years with an option for an additional two years . On April 30, 2021, the Company and KeyGene entered into a First Amended and Restated Framework Collaborative Research Agreement which extended the agreement term, from first-quarter 2024 to first-quarter 2027, and preserves the Company’s option for an additional 2-year extension, now through first quarter of 2029. The Company will exclusively own all results and all intellectual property relating to the results of the collaboration with KeyGene (the "Results”). The Company will pay royalties in varying amounts to KeyGene relating to the Company's commercialization in the Field of certain Results. The Company has granted KeyGene a license to commercialize the Results outside of the Field and KeyGene will pay royalties in varying amounts to the Company relating to KeyGene's commercialization outside of the Field of the Results. (2) The Company is also responsible for reimbursing NCSU for actual third-party patent costs incurred, including capitalized patent costs and patent maintenance costs. These costs vary from year to year and the Company has certain rights to direct the activities that result in these costs. (3) The Company is also responsible for the payment of certain costs, including, capitalized patent costs and patent maintenance costs, a running royalty on future net sales of products made from the sublicensed intellectual property, and a sharing of future sublicensing consideration received from sublicensing to third parties in all countries except for Canada. Anandia retains all patent rights, and is responsible for all patent maintenance, in Canada. (4) Various R&D growing agreements for hemp / cannabis and tobacco. (5) General corporate consulting agreements. Litigation Crede Settlement On June 19, 2019, the Company, Crede CG III, LTD. (“Crede”) and Terren Peizer (“Peizer”) participated in a settlement conference meeting as required by the United States District Court for the Southern District of New York (the “SDNY Court”) entitled Crede CG III, LTD. v. 22nd Century Group, Inc The Company accrued an expense related to the settlement of this case during the second quarter of 2019 in the amount of $1,891, which is equal to the fair value of the 990,000 shares of Company common stock on July 22, 2019. The accrual was reclassified to capital upon the issuance of the common stock during the third quarter of 2019. Class Action On January 21, 2019, Matthew Jackson Bull, a resident of Denver, Colorado, filed a Complaint against the Company, the Company’s then Chief Executive Officer, Henry Sicignano III, and the Company’s then Chief Financial Officer, John T. Brodfuehrer, in the United States District Court for the Eastern District of New York entitled: Matthew Bull, Individually and on behalf of all others similarly situated, v. 22nd Century Group, Inc., Henry Sicignano III, and John T. Brodfuehrer Case No. 1:19-cv-00409 On January 29, 2019, Ian M. Fitch, a resident of Essex County Massachusetts, filed a Complaint against the Company, the Company’s then Chief Executive Officer, Henry Sicignano III, and the Company’s then Chief Financial Officer, John T. Brodfuehrer, in the United States District Court for the Eastern District of New York entitled: Ian Fitch, Individually and on behalf of all others similarly situated, v. 22nd Century Group, Inc., Henry Sicignano III, and John T. Brodfuehrer Case No. 2:19-cv-00553 On May 28, 2019, the plaintiff in the Fitch Bull On September 16, 2019, pursuant to a joint motion by the parties, the Court in the Bull Plaintiffs in the Bull On January 29, 2020, the Company and Messrs. Sicignano and Brodfuehrer filed a Motion to Dismiss the Amended Complaint. On July 31, 2020, the Court heard oral arguments on the motion to dismiss. On January 14, 2021, the Court granted motion, dismissing all claims with prejudice. The Plaintiffs filed a notice of appeal on February 12, 2021 to the Second Circuit Court of Appeals. The Second Circuit has granted an expedited briefing schedule and Plaintiff’s/Appellant’s was filed on April 12, 2021 and the Company’s was filed on May 17, 2021. The Second Circuit heard oral arguments on September 2, 2021 and the matter remains pending with the Second Circuit. We believe that the claims are frivolous, meritless and that the Company and Messrs. Sicignano and Brodfuehrer have substantial legal and factual defenses to the claims. We intend to vigorously defend the Company and Messrs. Sicignano and Brodfuehrer against such claims. Shareholder Derivative Cases On February 6, 2019, Melvyn Klein, a resident of Nassau County New York, filed a shareholder derivative claim against the Company, the Company’s then Chief Executive Officer, Henry Sicignano III, the Company’s Chief Financial Officer, John T. Brodfuehrer, and each member of the Company’s Board of Directors in the United States District Court for the Eastern District of New York entitled: Melvyn Klein, derivatively on behalf of 22nd Century Group v. Henry Sicignano, III, Richard M. Sanders, Joseph Alexander Dunn, Nora B. Sullivan, James W. Cornell, John T. Brodfuehrer and 22nd Century Group, Inc Case No. 1:19-cv-00748 On February 11, 2019, Stephen Mathew filed a shareholder derivative claim against the Company, the Company’s then Chief Executive Officer, Henry Sicignano III, the Company’s Chief Financial Officer, John T. Brodfuehrer, and each member of the Company’s Board of Directors in the Supreme Court of the State of New York, County of Erie, entitled: Stephen Mathew, derivatively on behalf of 22nd Century Group, Inc. v. Henry Sicignano, III, John T. Brodfuehrer, Richard M. Sanders, Joseph Alexander Dunn, James W. Cornell, Nora B. Sullivan and 22nd Century Group, Inc., Index No. 801786/2019 Mathew Klein and factual defenses to the claims. We intend to vigorously defend the Company and the individual defendants against such claims. On June 10, 2019, Judy Rowley filed a shareholder derivative claim against the Company, the Company’s then Chief Executive Officer, Henry Sicignano III, the Company’s Chief Financial Officer, John T. Brodfuehrer, and each member of the Company’s Board of Directors in the Supreme Court of the State of New York, County of Erie, entitled: Judy Rowley, derivatively on behalf of 22nd Century Group, Inc. v. Henry Sicignano, III, Richard M. Sanders, Joseph Alexander Dunn, Nora B. Sullivan, James W. Cornell, John T. Brodfuehrer, and 22nd Century Group, Inc. Index No. 807214/2019 On January 15, 2020, Kevin Broccuto filed a shareholder derivative claim against the Company, the Company's then Chief Executive Officer, Henry Sicignano III, the Company's Chief Financial Officer, John T. Brodfuehrer, and certain members of the Company's prior Board of Directors in the District Court of the State of Nevada, County of Clark, entitled: Kevin Broccuto, derivatively on behalf of 22nd Century Group, Inc. v. James W. Cornell, Richard M. Sanders, Nora B. Sullivan, Henry Sicignano, III, and John T. Brodfuehrer, Case No. A-20-808599. On February 11, 2020, Jerry Wayne filed a shareholder derivative claim against the Company, the Company's then Chief Executive Officer, Henry Sicignano III, the Company's Chief Financial Officer, John T. Brodfuehrer, and certain members of the Company's prior Board of Directors in the District Court of the State of Nevada, County of Clark, entitled: Jerry Wayne, derivatively on behalf of 22nd Century Group, Inc. v. James W. Cornell, Richard M. Sanders, Nora B. Sullivan, Henry Sicignano, III, and John T. Brodfuehrer, Case No. A-20-808599. Mr. Wayne brings this action derivatively alleging generally the same allegations as the Brocutto case. The Complaint seeks unspecified monetary damages, corrective corporate governance actions, disgorgement of alleged profits and imposition of constructive trusts, and attorney's fees and costs. The Complaint also seeks to declare as unenforceable the Company's Bylaw requiring derivative lawsuits to be filed in Erie County, New York, where the Company is headquartered. On March 25, 2020, the Court ordered the Brocutto Wayne

LOSS PER COMMON SHARE

LOSS PER COMMON SHARE	12 Months Ended
LOSS PER COMMON SHARE	Dec. 31, 2021
LOSS PER COMMON SHARE
LOSS PER COMMON SHARE	NOTE 13. – LOSS PER COMMON SHARE The following table sets forth the computation of basic and diluted loss per common share for the years ended December 31, 2021, 2020 and 2019, respectively. Outstanding warrants, options, and restricted stock units were excluded from the calculation of diluted EPS as the effect was antidilutive. Year Ended December 31, 2021 2020 2019 (in thousands, except for per-share data) Net loss $ (32,609) $ (19,711) $ (26,558) Weighted average common shares outstanding - basic and diluted 156,208 138,813 125,883 Net loss per common share - basic and diluted $ (0.21) $ (0.14) $ (0.21) Anti-dilutive shares are as follows as of December 31: Warrants — 11,293 11,293 Options 5,171 6,581 7,837 Restricted stock units 3,165 2,938 951 8,336 20,812 20,081

EQUITY BASED COMPENSATION

EQUITY BASED COMPENSATION	12 Months Ended
EQUITY BASED COMPENSATION	Dec. 31, 2021
EQUITY- BASED COMPENSATION
EQUITY- BASED COMPENSATION	NOTE 14. – EQUITY BASED COMPENSATION On May 20, 2021, the stockholders of 22nd Century Group, Inc. (the “Company”) approved the 22nd Century Group, Inc. 2021 Omnibus Incentive Plan (the “2021 Plan”). The 2021 Plan allows for the granting of equity awards to eligible individuals over the life of the 2021 Plan, including the issuance of up to 5,000,000 shares of the Company’s common stock, in addition to any remaining shares under the Company’s 2014 Omnibus Incentive Plan pursuant to awards under the 2021 Plan. The 2021 Plan has a term of ten years and is administered by the Compensation Committee of the Company’s Board of Directors to determine the various types of incentive awards that may be granted to recipients under the 2021 Plan and the number of shares of common stock to underlie each such award under the 2021 Plan. As of December 31, 2021, the Company had available Restricted Stock Units (“RSUs”) Unvested RSUs Weighted Average Number of Grant-date Shares Fair Value in thousands $ per share Unvested at December 31, 2018 — $ — Granted 1,301 $ 2.21 Vested (100) $ 2.02 Forfeited (250) $ 2.02 Unvested at December 31, 2019 951 $ 2.15 Granted 2,885 $ 0.71 Vested (325) $ 1.07 Forfeited (573) $ 1.90 Unvested at December 31, 2020 2,938 $ 0.85 Granted 2,200 $ 3.25 Vested (1,660) $ 0.85 Forfeited (313) $ 1.04 Unvested at December 31, 2021 3,165 $ 2.50 The fair value of RSUs that vested during the years ended December 31, 2021 and 2020 was approximately $5,262 and $601, respectively, based on the stock price at the time of vesting. Stock Options. Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Price Term Value in thousands $ per share Outstanding at December 31, 2018 8,672 $ 1.54 Granted 600 $ 2.07 Exercised (75) $ 0.93 Forfeited (1,360) $ 2.09 Outstanding at December 31, 2019 7,837 $ 1.49 Exercised (399) $ 1.04 Forfeited (169) $ 1.83 Expired (688) $ 1.51 Outstanding at December 31, 2020 6,581 $ 1.50 Granted 235 $ 3.10 Exercised (984) $ 1.37 Forfeited (600) $ 1.00 Expired (61) $ 2.64 Outstanding at December 31, 2021 5,171 $ 1.65 3.6 years $ 7,431 Exercisable at December 31, 2021 4,836 $ 1.56 3.4 years $ 7,375 The intrinsic value of a stock option is the amount by which the current market value or the market value upon exercise of the underlying stock exceeds the exercise price of the option. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. No option awards were granted in 2020. The following assumptions were used for the years ended December 31, 2021 and 2019: 2021 2019 Risk-free interest rate (1) 0.54 % 1.54 % Expected dividend yield (2) — % — % Expected volatility (3) 87.92 % 70 % Expected term of stock options (4) 4.09 years 5.15 years (1) The risk-free interest rate is based on the period matching the expected term of the stock options based on the U.S. Treasury yield curve in effect on the grant date. (2) The expected dividend yield is assumed as zero. The Company has never paid cash dividends nor does it anticipate paying dividends in the foreseeable future. (3) The expected volatility is based on historical volatility of the Company’s stock. (4) The expected term represents the period of time that options granted are expected to be outstanding based on vesting date and contractual term. Compensation Expense Year Ended December 31, 2021 2020 2019 Sales, general, and administrative $ 3,821 $ 1,526 $ 3,166 Research and Development 162 128 374 Total RSUs and stock option compensation $ 3,983 $ 1,654 $ 3,540 As of December 31, 2021, unrecognized compensation expense amounted to $4,685 which is expected to be recognized over a weighted average period of approximately 0.8 years. In addition, there is approximately $517 of unrecognized compensation expense that requires the achievement of certain milestones which are not yet probable.

INCOME TAXES

INCOME TAXES	12 Months Ended
INCOME TAXES	Dec. 31, 2021
INCOME TAXES
INCOME TAXES	NOTE 15. – INCOME TAXES The following is a summary of the components giving rise to the income tax provision (benefit) for the years ended December 31, 2021, 2020 and 2019: 2021 2020 2019 Current: Federal $ — $ — $ — State — — — Total current $ — $ — $ — Deferred: Federal (7,566) (3,932) (5,607) State (1) (200) 55 Total deferred (7,567) (4,132) (5,552) Change in valuation allowance 7,581 4,170 5,552 Total income taxes $ 14 $ 38 $ — The provision (benefit) for income tax varies from that which would be expected based on applying the statutory federal rate to pre-tax accounting loss, including the effect of the change in the U.S. corporate income tax rates, as follows: 2021 2020 2019 Statutory federal rate (21.0) % (21.0) % (21.0) % Other items 0.5 (0.3) (0.1) Litigation Settlement — — 1.5 Derivative liability — — — Stock based compensation (2.7) 0.7 1.8 Research and development credit carryforward (0.1) 0.2 (3.3) State tax provision, net of federal benefit — (0.8) 0.2 Equity investment — — — Federal tax rate change — — — Valuation allowance 23.3 21.4 20.9 Effective tax rate (benefit) provision — % 0.2 % — % Individual components of deferred taxes consist of the following as of December 31: 2021 2020 2019 Deferred tax assets: Net operating loss carry-forward $ 24,859 $ 18,498 $ 14,996 Inventory 104 115 52 Stock-based compensation 1,326 1,099 1,049 Start-up expenditures 177 199 221 Research and development credit carryforward 1,192 1,171 1,209 Accrued bonus 411 423 200 Severance liability 50 122 134 Unrealized loss on investments 1,366 371 40 Operating lease obligations 365 52 127 Capital loss on investment 107 — — Other 18 18 22 $ 29,975 $ 22,068 $ 18,050 Deferred tax liabilities: Machinery and equipment (254) (237) (239) Patents and trademarks (373) (358) (351) Gain on investment — (13) (104) Accrued expense — (24) (51) Operating lease right-of-use assets (362) (52) (126) Other intangible assets (259) (224) (189) (1,248) (908) (1,060) Valuation allowance (28,779) (21,198) (16,990) Net deferred taxes $ (52) $ (38) $ — The Company has net operating loss (“NOL”) carryforwards of approximately $70,658 as of December 31, 2021, that do not expire. The Company had accumulated an NOL carryforward of approximately $46,920 through December 31, 2017 and this NOL carryforward begins to expire in 2031. As of December 31, 2021, the Company has a research and development credit carryforward of approximately $1,192 that begins to expire in 2031. The Company has a capital loss carryover of approximately $510 as of December 31, 2021, which expires in 2026. Utilization of these NOL carryforwards may be subject to an annual limitation in the case of equity ownership changes, as defined by law. Due to the uncertainty of the Company’s ability to generate sufficient taxable income in the future, the Company has recorded a valuation allowance to reduce the net deferred tax asset to zero. These carryforwards are included in the net deferred tax asset that has been fully offset by the valuation allowance. ASC 740 provides guidance on the financial statement recognition and measurement for uncertain income tax positions that are taken or expected to be taken in a company’s income tax return. The Company has evaluated its tax positions and believes there are no uncertain tax positions as of December 31, 2021.

REVENUE RECOGNITION

REVENUE RECOGNITION	12 Months Ended
REVENUE RECOGNITION	Dec. 31, 2021
REVENUE RECOGNITION
REVENUE RECOGNITION	NOTE 16. – REVENUE RECOGNITION The Company recognizes revenue when it satisfies a performance obligation by transferring control of the product to a customer. The Company’s customer contracts consist of obligations to manufacture the customer’s branded filtered cigars and cigarettes. For certain contracts, the performance obligation is satisfied over time as the Company determines, due to contract restrictions, it does not have an alternative use of the product, and it has an enforceable right to payment as the product is manufactured. The Company recognizes revenue under those contracts at the unit price stated in the contract based on the units manufactured. Revenue from the sale of the Company’s products, which includes excise taxes and shipping and handling charges billed to customers, is recognized net of cash discounts, sales returns and allowances. There was no allowance for discounts or returns and allowances at December 31, 2021 and December 31, 2020. Excise taxes recorded in Cost of Goods Sold on the Consolidated Statement of Operations and Comprehensive Loss for 2021, 2020, and 2019 were $10,135, $9,859, and $9,187, respectively. Contract Assets and Liabilities Unbilled receivables (contract assets) represent revenues recognized for performance obligations that have been satisfied but have not been billed. These receivables are included as Accounts receivable, net on the Consolidated Balance Sheets. Customer payment terms vary depending on the terms of each customer contract, but payment is generally due prior to product shipment or within extended credit terms up to twenty-one (21) days after shipment. Deferred revenue (contract liabilities) relates to down payments received from customers in advance of satisfying a performance obligation. This deferred revenue is included as Deferred income on the Consolidated Balance Sheets. Total contract assets and contract liabilities are as follows: December 31, December 31, 2021 2020 Unbilled receivables $ 178 $ 349 Deferred revenue (119) (272) Net contract assets $ 59 $ 77 Disaggregation of Revenue The Company’s net sales revenue is derived from customers located primarily in the United States of America and is disaggregated by the timing of revenue recognition—net sales transferred over time and net sales transferred at a point in time. Revenue is primarily related to contract manufacturing. Year Ended December 31, 2021 2020 2019 Net sales-over time $ 21,061 $ 16,326 $ 16,466 Net sales-point in time 9,887 11,785 9,367 Total Revenue $ 30,948 $ 28,111 $ 25,833 The Company had certain customers whose revenue individually represented 10% or more of the Company’s total revenue. For the year ended December 31, 2021, three customers accounted for approximately 84% of total revenue. For the year ended December 31, 2020, two customers accounted for approximately 91% of total revenue. For the year ended December 31, 2019, three customers accounted for approximately 93% of total revenue.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	12 Months Ended
SUBSEQUENT EVENT	Dec. 31, 2021
SUBSEQUENT EVENT
SUBSEQUENT EVENT	NOTE 17. – SUBSEQUENT EVENT Investment in Change Agronomy On December 10, 2021, we entered into a subscription agreement to invest £500 (pounds sterling, in thousands), in exchange for 592,888 ordinary shares of Change Agronomy Ltd. (“CAL”), a private company existing under the laws of England, at a price per share of £0.84333. CAL is a vertically integrated sustainable industrial hemp business that combines world-class genetics with leading agronomic techniques and infrastructure to provide full-service industrial hemp products to multiple global end markets. CAL presently has operations in Manitoba, Canada, and Italy. This equity investment was part of an Offer for Subscription by CAL for a minimum total of £3,000 at the same price per ordinary share. Approximately U.S. $682 in funds were wired to CAL on January 26, 2022, and our investment of £500 equates to approximately 1.8% of CAL’s total equity.

SCHEDULE II-VALUATION AND QUALI

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	Dec. 31, 2021
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	22nd CENTURY GROUP, INC. AND SUBSIDIARIES SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS ($ in thousands) Column A Column B Column C Column D Column E Balance at beginning of period Charged to costs and expenses Charged to other accounts Deductions Balance at end of period Valuation allowance on net deferred tax assets: Year Ended December 31, 2021 $ 21,198 $ 7,581 $ — $ — $ 28,779 Year Ended December 31, 2020 $ 16,990 $ 4,208 $ — $ — $ 21,198 Year Ended December 31, 2019 $ 11,438 $ 5,552 $ — $ — $ 16,990 Allowance for slow moving or obsolete inventory: Year Ended December 31, 2021 $ 100 $ 317 $ — $ (317) $ 100 Year Ended December 31, 2020 $ 100 $ 521 $ — $ (521) $ 100 Year Ended December 31, 2019 $ 100 $ 985 $ — $ (985) $ 100

NATURE OF BUSINESS AND SUMMAR_2

NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2021
NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation	Principles of Consolidation
Nature of Business	Nature of Business
COVID-19 Pandemic	COVID-19 Pandemic
Preferred stock authorized	Preferred stock authorized
Foreign currency translation	Foreign currency translation–
Concentration of Credit Risk	Concentration of Credit Risk
Cash and cash equivalents	Cash and cash equivalents –
Short-term investment securities	Short-term investment securities securities, and commercial paper with maturities greater than three months at the time of acquisition. The Company’s short-term investment securities are carried at fair value within current assets on the Company’s Consolidated Balance Sheets. The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security. The Company’s investment policy states that all investment securities must have a maximum maturity of twenty-four
Accounts receivable	Accounts receivable
Inventory	Inventory
Property, plant and equipment	Property, plant and equipment –
Intangible Assets	Intangible Assets The Company’s capitalized intellectual property costs are amortized using the straight-line method over the remaining statutory life of the patent assets in each of the Company’s patent families, which have estimated expiration dates ranging from 2026 to 2042. Periodic maintenance or renewal fees are expensed as incurred. Annual minimum license fees are charged to expense. License fees paid for third-party intellectual property are amortized on a straight-line basis over the last to expire patents, which have expected expiration dates from 2028 through 2036. The Company believes that costs associated with becoming a signatory to the MSA, costs related to the acquisition of a predicate cigarette brand and trademarks have indefinite lives. As such, no amortization is taken. At each reporting period, the Company evaluates whether events and circumstances continue to support the indefinite-lived classification.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Property, plant, and equipment Intangibles, Goodwill, and Other Intangible assets subject to amortization are reviewed for strategic importance and commercialization opportunity prior to expiration. If it is determined that the asset no longer supports the Company’s strategic objectives and/or will not be commercially viable prior to expiration, the asset is impaired. In addition, the Company will assess the expected future undiscounted cash flows for its intellectual property based on consideration of future market and economic conditions, competition, federal and state regulations, and licensing opportunities. If the carrying value of such assets are not recoverable, the carrying value will be reduced to fair value and record the difference as an impairment. Indefinite-lived intangible asset carrying values are reviewed at least annually or more frequently if events or changes in circumstances indicate that it is more likely than not that an impairment exists. The Company first performs a qualitative assessment and considers its current strategic objectives, future market and economic conditions, competition, and federal and state regulations to determine if an impairment is more likely than not. If it is determined that an impairment is more likely than not, a quantitative assessment is performed to compare the asset carrying value to fair value.
Right-of-use ("ROU") assets and Lease Obligations	Right-of-use (“ROU”) assets and Lease Obligations Refer to Note 4 for additional information regarding our ROU assets and liabilities.
Income Taxes	Income Taxes As a result of the Company’s history of cumulative net operating losses and the uncertainty of their future utilization, the Company has established a valuation allowance to fully offset its net deferred tax assets as of December 31, 2021 and December 31, 2020. Additionally, the Company has elected to present other comprehensive income items relating to net unrealized gains on short-term investment securities gross and not net of taxes. The Company’s federal and state tax returns for the years ended December 31, 2018 through December 31, 2020 are currently open to audit under the statutes of limitations. There are no pending audits as of December 31, 2021.
Stock Based Compensation	Stock Based Compensation
Revenue Recognition	Revenue Recognition
Derivatives	Derivatives
Research and Development	Research and Development
Loss Per Common Share	Loss Per Common Share
Use of Estimates	Use of Estimates
Fair Value of Financial Instruments	Fair Value of Financial Instruments
Investments	Investments
Loss Contingencies	Loss Contingencies
Recent Accounting Pronouncement(s)	Recent Accounting Pronouncement(s) – In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments.” The standard replaces the incurred loss model with the current expected credit loss (CECL) model to estimate credit losses for financial assets measured at amortized cost and certain off-balance sheet credit exposures. The CECL model requires companies to estimate credit losses expected over the life of the financial assets based on historical experience, current conditions and reasonable and supportable forecasts. The provisions of the ASU are effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years—excluding small reporting companies (SRCs), based on a determination date as of November 15, 2019, which have an effective date beginning after December 15, 2022 and interim periods within those fiscal years. The Company is evaluating the expected impacts of the ASU. We consider the applicability and impact of all ASUs. If the ASU is not listed above, it was determined that the ASU was either not applicable or would have an immaterial impact on our financial statements and related disclosures.

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
INVENTORY (Tables)	Dec. 31, 2021
INVENTORY
Schedule of Inventories	December 31, December 31, 2021 2020 Inventory - tobacco leaf $ 1,352 $ 821 Inventory - hemp/cannabis 10 — Inventory - finished goods Cigarettes and filtered cigars 256 171 Inventory - raw materials Cigarette and filtered cigar components 1,363 1,142 Less: inventory reserve (100) (100) $ 2,881 $ 2,034

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	12 Months Ended
PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	Dec. 31, 2021
PROPERTY, PLANT AND EQUIPMENT, NET
Schedule of Property, plant and equipment, net	December 31, December 31, Useful Life 2021 2020 Land $ 1,665 $ — Building and leasehold improvements 7 309 123 Manufacturing equipment 3 5,541 4,893 Office furniture, fixtures and equipment 3 139 20 Laboratory equipment 5 years 198 117 Construction in progress 1,289 — Less: accumulated depreciation (3,300) (2,670) Property, plant and equipment, net $ 5,841 $ 2,483

RIGHT-OF-USE ASSETS, LEASE OB_2

RIGHT-OF-USE ASSETS, LEASE OBLIGATIONS, AND OTHER LEASES (Tables)	12 Months Ended
	Dec. 31, 2021
RIGHT-OF-USE ASSETS, LEASE OBLIGATIONS, AND OTHER LEASES
Summary of discount rate and remaining lease terms	Weighted average remaining lease term in years 4.6 Weighted average discount rate 3.4 %
Schedule of future minimum lease payments	2022 373 2023 429 2024 448 2025 418 2026 111 Thereafter 108 Total lease payments 1,887 Less: imputed interest (147) Total $ 1,740

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
INTANGIBLE ASSETS (Tables)	Dec. 31, 2021
INTANGIBLE ASSETS
Schedule of Intangible Assets	December 31, December 31, 2021 2020 Intangible assets, net Patent and trademark costs $ 5,991 $ 5,667 Less: accumulated amortization (3,303) (2,936) Patent and trademark costs, net 2,688 2,731 License fees 3,876 3,876 Less: accumulated amortization (1,197) (948) License fees, net 2,679 2,928 MSA signatory costs 2,202 2,202 License fee for predicate cigarette brand 350 350 $ 7,919 $ 8,211

INVESTMENTS & OTHER ASSETS (Tab

INVESTMENTS & OTHER ASSETS (Tables)	12 Months Ended
INVESTMENTS & OTHER ASSETS (Tables)	Dec. 31, 2021
Investment in Panacea
Marketable Securities [Line Items]
Schedule of carrying value of investments	December 31, December 31, 2021 2020 Panacea preferred stock $ — $ 5,173 Panacea stock warrant — 1,124 Accrued interest on convertible note receivable (included within prepaid expenses and other assets) — 170 Convertible note receivable — 5,876 Promissory note receivable 3,741 — Panacea Holdings common stock 2,340 — Total $ 6,082 $ 12,343
Aurora Cannabis Inc
Marketable Securities [Line Items]
Schedule of carrying value of investments	December 31, December 31, 2021 2020 Aurora stock warrants $ 5 $ 239 Panacea preferred stock — 5,173 Panacea stock warrant — 1,124 Panacea Holdings common stock 2,340 — Total Investments $ 2,345 $ 6,536 Convertible note receivable $ — $ 5,876 Promissory note receivable $ 3,741 $ —

FAIR VALUE MEASUREMENTS AND S_2

FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS (Tables)	12 Months Ended
FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS (Tables)	Dec. 31, 2021
FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS
Schedule of assets and liabilities measured at fair value	Fair Value December 31, 2021 Level 1 Level 2 Level 3 Total Assets Short-term investment securities: Money market funds $ 8,919 $ — $ — $ 8,919 Corporate bonds — 38,481 — 38,481 Total short-term investment securities $ 8,919 $ 38,481 $ — $ 47,400 Investment - Aurora stock warrants $ — $ — $ 5 $ 5 Investment - Panacea Holdings common shares $ 2,340 $ — $ — $ 2,340 Fair Value December 31, 2020 Level 1 Level 2 Level 3 Total Assets Short-term investment securities: Money market funds $ 8,636 $ — $ — $ 8,636 Corporate bonds — 12,677 — 12,677 Total short-term investment securities $ 8,636 $ 12,677 $ — $ 21,313 Investment - Aurora stock warrants $ — $ — $ 239 $ 239 Investment - Panacea preferred stock $ — $ — $ 5,173 $ 5,173 Convertible note receivable $ — $ — $ 5,876 $ 5,876
Schedule of the changes in fair value of Level 3 investments	Fair Value at December 31, 2019 $ 11,127 Unrealized loss as a result of change in fair value (434) Accretion of interest on Panacea investment 595 Fair Value at December 31, 2020 $ 11,288 Unrealized loss on Aurora stock warrants (233) Accretion of interest on Panacea preferred stock 142 Panacea investment conversion (11,192) Fair Value at December 31, 2021 $ 5
Schedule of available-for-sale securities reconciliation	Available for Sale Debt Securities December 31, 2021 Amortized Gross Gross Cost Unrealized Unrealized Fair Basis Gains Losses Value Corporate bonds $ 38,643 $ 1 $ (163) $ 38,481 Available for Sale Debt Securities December 31, 2020 Amortized Gross Gross Cost Unrealized Unrealized Fair Basis Gains Losses Value Corporate bonds $ 12,603 $ 74 $ — $ 12,677 Convertible note receivable 5,876 — — 5,876 Investment - Panacea preferred stock 5,173 — — 5,173 $ 23,652 $ 74 $ — $ 23,726
Schedule of available for sale securities classified by contractual maturity	Available for Sale Debt Securities December 31, 2021 December 31, 2020 Amortized Amortized Cost Basis Fair Value Cost Basis Fair Value Due in one year or less $ 8,286 $ 8,280 $ 11,692 $ 11,753 Due after one year through five years 30,357 30,201 11,960 11,973 $ 38,643 $ 38,481 $ 23,652 $ 23,726

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
NOTES PAYABLE (Tables)	Dec. 31, 2021
NOTES PAYABLE
Schedule of notes payable balances	December 31, December 31, 2021 2020 License Fees $ — $ 293 D&O Insurance 596 246 Total current notes payable $ 596 $ 539

CAPITAL RAISE AND WARRANTS FO_2

CAPITAL RAISE AND WARRANTS FOR COMMON STOCK (Tables)	12 Months Ended
CAPITAL RAISE AND WARRANTS FOR COMMON STOCK (Tables)	Dec. 31, 2021
CAPITAL RAISE AND WARRANTS FOR COMMON STOCK
Schedule of warrant activity	Number of Warrants Warrants outstanding at December 31, 2018 11,293,211 Exercised (11,293,211) Issued 11,293,211 Warrants outstanding at December 31, 2019 11,293,211 Exercised — Issued — Warrants outstanding at December 31, 2020 11,293,211 Exercised (11,293,211) Issued — Warrants outstanding at December 31, 2021 —

COMMITMENTS & CONTINGENCIES (Ta

COMMITMENTS & CONTINGENCIES (Tables)	12 Months Ended
COMMITMENTS & CONTINGENCIES (Tables)	Dec. 31, 2021
COMMITMENTS AND CONTINGENCIES
Contractual Obligation, Fiscal Year Maturity [Table Text Block]	Future Commitments Commitment Counter Party Product Relationship Commitment Type 2022 2023 2024 2025 2026 & After Total Research Agreement KeyGene Hemp / Cannabis Contract fee $ 1,150 $ 1,200 $ 1,227 $ 1,264 $ 1,630 $ 6,471 (1) License Agreement NCSU Tobacco Annual royalty fee 225 — — — — 225 (2), (3) License Agreement NCSU Tobacco Minimum annual royalty 50 50 50 50 550 750 (2) License Agreement NCSU Tobacco Minimum annual royalty 50 50 50 50 450 650 (2) Sublicense Agreement Anandia Laboratories, Inc. Hemp / Cannabis Annual license fee 10 10 10 10 100 140 (3) Growing Agreements Various Various Contract fee 38 — — — — 38 (4) Consulting Agreements Various Various Contract fee 1,370 808 — — — 2,178 (5) $ 2,893 $ 2,118 $ 1,337 $ 1,374 $ 2,730 $ 10,452 (1) Exclusive agreement with the Company with respect to the Cannabis Sativa L. plant (the "Field"). The initial term of the agreement was five years with an option for an additional two years . On April 30, 2021, the Company and KeyGene entered into a First Amended and Restated Framework Collaborative Research Agreement which extended the agreement term, from first-quarter 2024 to first-quarter 2027, and preserves the Company’s option for an additional 2-year extension, now through first quarter of 2029. The Company will exclusively own all results and all intellectual property relating to the results of the collaboration with KeyGene (the "Results”). The Company will pay royalties in varying amounts to KeyGene relating to the Company's commercialization in the Field of certain Results. The Company has granted KeyGene a license to commercialize the Results outside of the Field and KeyGene will pay royalties in varying amounts to the Company relating to KeyGene's commercialization outside of the Field of the Results. (2) The Company is also responsible for reimbursing NCSU for actual third-party patent costs incurred, including capitalized patent costs and patent maintenance costs. These costs vary from year to year and the Company has certain rights to direct the activities that result in these costs. (3) The Company is also responsible for the payment of certain costs, including, capitalized patent costs and patent maintenance costs, a running royalty on future net sales of products made from the sublicensed intellectual property, and a sharing of future sublicensing consideration received from sublicensing to third parties in all countries except for Canada. Anandia retains all patent rights, and is responsible for all patent maintenance, in Canada. (4) Various R&D growing agreements for hemp / cannabis and tobacco. (5) General corporate consulting agreements.

LOSS PER COMMON SHARE (Tables)

LOSS PER COMMON SHARE (Tables)	12 Months Ended
LOSS PER COMMON SHARE (Tables)	Dec. 31, 2021
LOSS PER COMMON SHARE
Schedule of computation of basic and diluted earnings per common share	Year Ended December 31, 2021 2020 2019 (in thousands, except for per-share data) Net loss $ (32,609) $ (19,711) $ (26,558) Weighted average common shares outstanding - basic and diluted 156,208 138,813 125,883 Net loss per common share - basic and diluted $ (0.21) $ (0.14) $ (0.21) Anti-dilutive shares are as follows as of December 31: Warrants — 11,293 11,293 Options 5,171 6,581 7,837 Restricted stock units 3,165 2,938 951 8,336 20,812 20,081

EQUITY- BASED COMPENSATION (Tab

EQUITY- BASED COMPENSATION (Tables)	12 Months Ended
EQUITY- BASED COMPENSATION (Tables)	Dec. 31, 2021
EQUITY- BASED COMPENSATION
Summary of changes in unvested restricted stock	Unvested RSUs Weighted Average Number of Grant-date Shares Fair Value in thousands $ per share Unvested at December 31, 2018 — $ — Granted 1,301 $ 2.21 Vested (100) $ 2.02 Forfeited (250) $ 2.02 Unvested at December 31, 2019 951 $ 2.15 Granted 2,885 $ 0.71 Vested (325) $ 1.07 Forfeited (573) $ 1.90 Unvested at December 31, 2020 2,938 $ 0.85 Granted 2,200 $ 3.25 Vested (1,660) $ 0.85 Forfeited (313) $ 1.04 Unvested at December 31, 2021 3,165 $ 2.50
Schedule of stock option activity	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Price Term Value in thousands $ per share Outstanding at December 31, 2018 8,672 $ 1.54 Granted 600 $ 2.07 Exercised (75) $ 0.93 Forfeited (1,360) $ 2.09 Outstanding at December 31, 2019 7,837 $ 1.49 Exercised (399) $ 1.04 Forfeited (169) $ 1.83 Expired (688) $ 1.51 Outstanding at December 31, 2020 6,581 $ 1.50 Granted 235 $ 3.10 Exercised (984) $ 1.37 Forfeited (600) $ 1.00 Expired (61) $ 2.64 Outstanding at December 31, 2021 5,171 $ 1.65 3.6 years $ 7,431 Exercisable at December 31, 2021 4,836 $ 1.56 3.4 years $ 7,375
Schedule of fair value assumptions	2021 2019 Risk-free interest rate (1) 0.54 % 1.54 % Expected dividend yield (2) — % — % Expected volatility (3) 87.92 % 70 % Expected term of stock options (4) 4.09 years 5.15 years (1) The risk-free interest rate is based on the period matching the expected term of the stock options based on the U.S. Treasury yield curve in effect on the grant date. (2) The expected dividend yield is assumed as zero. The Company has never paid cash dividends nor does it anticipate paying dividends in the foreseeable future. (3) The expected volatility is based on historical volatility of the Company’s stock. (4) The expected term represents the period of time that options granted are expected to be outstanding based on vesting date and contractual term.
Schedule of compensation costs related to restricted stock and stock options	Year Ended December 31, 2021 2020 2019 Sales, general, and administrative $ 3,821 $ 1,526 $ 3,166 Research and Development 162 128 374 Total RSUs and stock option compensation $ 3,983 $ 1,654 $ 3,540

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
INCOME TAXES (Tables)	Dec. 31, 2021
INCOME TAXES
Summary of the components giving rise to the income tax provision (benefit)	2021 2020 2019 Current: Federal $ — $ — $ — State — — — Total current $ — $ — $ — Deferred: Federal (7,566) (3,932) (5,607) State (1) (200) 55 Total deferred (7,567) (4,132) (5,552) Change in valuation allowance 7,581 4,170 5,552 Total income taxes $ 14 $ 38 $ —
Schedule of effective income tax rate reconciliation	2021 2020 2019 Statutory federal rate (21.0) % (21.0) % (21.0) % Other items 0.5 (0.3) (0.1) Litigation Settlement — — 1.5 Derivative liability — — — Stock based compensation (2.7) 0.7 1.8 Research and development credit carryforward (0.1) 0.2 (3.3) State tax provision, net of federal benefit — (0.8) 0.2 Equity investment — — — Federal tax rate change — — — Valuation allowance 23.3 21.4 20.9 Effective tax rate (benefit) provision — % 0.2 % — %
Schedule of deferred tax assets and liabilities	2021 2020 2019 Deferred tax assets: Net operating loss carry-forward $ 24,859 $ 18,498 $ 14,996 Inventory 104 115 52 Stock-based compensation 1,326 1,099 1,049 Start-up expenditures 177 199 221 Research and development credit carryforward 1,192 1,171 1,209 Accrued bonus 411 423 200 Severance liability 50 122 134 Unrealized loss on investments 1,366 371 40 Operating lease obligations 365 52 127 Capital loss on investment 107 — — Other 18 18 22 $ 29,975 $ 22,068 $ 18,050 Deferred tax liabilities: Machinery and equipment (254) (237) (239) Patents and trademarks (373) (358) (351) Gain on investment — (13) (104) Accrued expense — (24) (51) Operating lease right-of-use assets (362) (52) (126) Other intangible assets (259) (224) (189) (1,248) (908) (1,060) Valuation allowance (28,779) (21,198) (16,990) Net deferred taxes $ (52) $ (38) $ —

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	12 Months Ended
REVENUE RECOGNITION (Tables)	Dec. 31, 2021
REVENUE RECOGNITION
Schedule of contract assets and liabilities	December 31, December 31, 2021 2020 Unbilled receivables $ 178 $ 349 Deferred revenue (119) (272) Net contract assets $ 59 $ 77
Schedule of disaggregation of revenue	Year Ended December 31, 2021 2020 2019 Net sales-over time $ 21,061 $ 16,326 $ 16,466 Net sales-point in time 9,887 11,785 9,367 Total Revenue $ 30,948 $ 28,111 $ 25,833

NATURE OF BUSINESS AND SUMMAR_3

NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
	Dec. 31, 2021subsidiary
NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of subsidiaries	4
Maximum maturity date of securities	24 months
Directors
NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Vesting period	1 year
Officers and employees
NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Vesting period	3 years
Twenty Second Century Ltd
NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of subsidiaries	2
Botanical Genetics
NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of subsidiaries	1

INVENTORY (Details)

INVENTORY (Details) - USD ($) $ in Thousands	12 Months Ended
INVENTORY (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventory [Line Items]
Inventory - tobacco leaf	$ 1,352	$ 821
Inventory - hemp/cannabis	10
Inventory - finished goods	256	171
Inventory - raw materials	1,363	1,142
Less: inventory reserve	(100)	(100)
Inventory, Net	2,881	2,034
Inventory write-off	317	521	$ 985
Research and Development
Inventory [Line Items]
Inventory write-off		361
Cost of Sales
Inventory [Line Items]
Inventory write-off	$ 317	$ 161

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
PROPERTY, PLANT AND EQUIPMENT, NET
Less: accumulated depreciation	$ (3,300)	$ (2,670)
Total property, plant and equipment	5,841	2,483
Depreciation expense	633	688	$ 589
Land
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Gross	1,665
Building and Leasehold improvements
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Gross	$ 309	123
Building and Leasehold improvements \| Maximum
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Useful Life	40 years
Building and Leasehold improvements \| Minimum
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Useful Life	7 years
Manufacturing equipment
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Gross	$ 5,541	4,893
Manufacturing equipment \| Maximum
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Useful Life	10 years
Manufacturing equipment \| Minimum
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Useful Life	3 years
Office furniture, fixtures and equipment
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Gross	$ 139	20
Office furniture, fixtures and equipment \| Maximum
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Useful Life	5 years
Office furniture, fixtures and equipment \| Minimum
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Useful Life	3 years
Laboratory equipment
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Gross	$ 198	$ 117
Property, Plant and Equipment, Useful Life	5 years
Construction in Progress
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Gross	$ 1,289

RIGHT-OF-USE ASSETS, LEASE OB_3

RIGHT-OF-USE ASSETS, LEASE OBLIGATIONS AND OTHER LEASES (Details) ft² in Thousands, $ in Thousands	Oct. 18, 2021USD ($)item	Jul. 28, 2021USD ($)ft²	Jan. 15, 2021USD ($)item	Dec. 31, 2021USD ($)item	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
RIGHT-OF-USE ASSETS, LEASE OBLIGATIONS, AND OTHER LEASES
Weighted average remaining lease term in years				4 years 7 months 6 days
Weighted average discount rate				3.40%
Future minimum lease payments
2022				$ 373
2023				429
2024				448
2025				418
2026				111
Thereafter				108
Total lease payments				1,887
Less: imputed interest				(147)
Operating Lease, Liability				1,740
Operating Lease, Expense				$ 301	$ 335	$ 250
Number of one-year renewal options \| item				3
Manufacturing Facility And Warehouse In North Carolina
Future minimum lease payments
Monthly base rent	$ 17
Initial lease term	24 months
Number of renewal options \| item	1
Renewal term	24 months
Laboratory Space In Buffalo
Future minimum lease payments
Monthly base rent			$ 6
Base Rent Annual Increase, as a percent			2.50%
Initial lease term			36 months
Number of renewal options \| item			2
Renewal term			24 months
Research And Development Laboratory In Rockville, MD
Future minimum lease payments
Area under operating lease \| ft²		4
Monthly base rent		$ 12
Base Rent Annual Increase, as a percent		2.50%
Initial lease term		51 months
Rent abatement period		5 months

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	12 Months Ended
INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Intangible assets, net
Intangible assets, net	$ 7,919	$ 8,211
Amortization expense	615	658	$ 836
Impairment of intangible assets	78	176	1,142
Intangible assets written off, cost		448	2,092
Intangible assets written off, accumulated amortization		302	$ 950
MSA Signatory Costs
Intangible assets, net
Indefinite-lived intangible assets	2,202	2,202
Licensing agreements
Intangible assets, net
Indefinite-lived intangible assets	350	350
Patent and Trademark
Intangible assets, net
Gross	5,991	5,667
Less: accumulated amortization	(3,303)	(2,936)
Total	2,688	2,731
Impairment of intangible assets	78
Estimated annual average amortization expense:
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	387
Finite-Lived Intangible Assets, Amortization Expense, Year Two	387
Finite-Lived Intangible Assets, Amortization Expense, Year Three	387
Finite-Lived Intangible Assets, Amortization Expense, Year Four	387
Finite-Lived Intangible Assets, Amortization Expense, Year Five	387
Licensing agreements
Intangible assets, net
Gross	3,876	3,876
Less: accumulated amortization	(1,197)	(948)
Total	2,679	$ 2,928
Estimated annual average amortization expense:
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	249
Finite-Lived Intangible Assets, Amortization Expense, Year Two	249
Finite-Lived Intangible Assets, Amortization Expense, Year Three	249
Finite-Lived Intangible Assets, Amortization Expense, Year Four	249
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 249

INVESTMENTS & OTHER ASSETS - To

INVESTMENTS & OTHER ASSETS - Total carrying value (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020	Dec. 03, 2019
INVESTMENTS & OTHER ASSETS
Investments	$ 2,345		$ 6,536
Note receivable	3,741		5,876
Preferred stock
INVESTMENTS & OTHER ASSETS
Investments			5,173
Common Stock
INVESTMENTS & OTHER ASSETS
Investments	2,340
Aurora Cannabis Inc \| Warrants
INVESTMENTS & OTHER ASSETS
Investments	5		239
Investment in Panacea
INVESTMENTS & OTHER ASSETS
Investments	7			$ 13,297
Accrued interest on convertible note receivable (included within prepaid expenses and other assets)			170
Note receivable	3,741	$ 3,684	5,876
Total	6,082		12,343
Investment in Panacea \| Warrants
INVESTMENTS & OTHER ASSETS
Investments			1,124
Investment in Panacea \| Preferred stock
INVESTMENTS & OTHER ASSETS
Investments			$ 5,173
Investment in Panacea \| Common Stock
INVESTMENTS & OTHER ASSETS
Investments	$ 2,340
Exactus
INVESTMENTS & OTHER ASSETS
Investments		$ 9,102

INVESTMENTS AND OTHER ASSETS -

INVESTMENTS AND OTHER ASSETS - Investment in Panacea Life Sciences, Inc (Details)	Oct. 25, 2021shares	Jun. 30, 2021USD ($)ft²shares	Dec. 03, 2019USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2021USD ($)item$ / sharesshares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 22, 2019$ / shares
INVESTMENTS & OTHER ASSETS
Long-term Investments					$ 2,345,000	$ 6,536,000
Stock issued in connection with Panacea investment			$ 1,297,000				$ 1,297,000
Note receivable					3,741,000	5,876,000
Exercise price \| $ / shares								$ 1.11
Impairment of Panacea investment						1,741,000
Investments, Fair Value Disclosure [Abstract]
Gain on Panacea investment conversion					2,548,000
Preferred stock
INVESTMENTS & OTHER ASSETS
Long-term Investments						5,173,000
Investment in Panacea
INVESTMENTS & OTHER ASSETS
Long-term Investments			13,297,000		$ 7,000
Amount paid to acquire investments			$ 12,000,000
Ownership percentage (in percent)			15.80%
Number of instruments comprising the investment \| item					3
Note receivable		$ 3,684,000			$ 3,741,000	5,876,000
Exercise price \| $ / shares					$ 2.344
Note receivable, face amount		$ 4,300,000	$ 7,000
Note receivable term					5 years
Note receivable interest rate		0.00%			10.00%
Dividend rate					10.00%
Number of years for acceleration of exercise date			2 years
Original issuance price			$ 7,000,000
Cancellation of note receivable					$7,000
Interest Receivable						170,000
Value before impairment						7,170,000
Impairment of Panacea investment						679,000
Area of Land \| ft²		224
Investments, Fair Value Disclosure [Abstract]
Total					$ 6,082,000	12,343,000
Gain on Panacea investment conversion		$ 2,548,000
Panacea conversion assets included in acquisition of property, plant and equipment		2,248,000			$ 7,170,000
Stock received in conversion, value		500,000
Note receivable, discount		616,000
Investment in Panacea \| Preferred stock
INVESTMENTS & OTHER ASSETS
Long-term Investments						5,173,000
Investment in Panacea \| Warrants
INVESTMENTS & OTHER ASSETS
Long-term Investments						$ 1,124,000
Ownership percentage (in percent)					51.00%
Impairment of Panacea investment				$ 1,062,000
Investment in Panacea \| Warrants \| Volatility
INVESTMENTS & OTHER ASSETS
Warrants measurement input			0.70
Investment in Panacea \| Warrants \| Discount for lack of marketability
INVESTMENTS & OTHER ASSETS
Warrants measurement input			0.25
Investment in Panacea \| Warrants \| Risk-free rate
INVESTMENTS & OTHER ASSETS
Warrants measurement input			0.02
Exactus
INVESTMENTS & OTHER ASSETS
Long-term Investments		$ 9,102,000
Investments, Fair Value Disclosure [Abstract]
Stock received in conversion, shares \| shares		91,016,026
Reverse stock split, ratio	0.035714
Number of shares held in investee \| shares	3,250,573				91,016,026

INVESTMENTS & OTHER ASSETS - In

INVESTMENTS & OTHER ASSETS - Investment in Aurora Cannabis, Inc (Details)	3 Months Ended	12 Months Ended
	Jun. 30, 2020$ / sharesshares	Dec. 31, 2018$ / sharesshares	Dec. 22, 2019$ / shares
INVESTMENTS & OTHER ASSETS
Exercise price			$ 1.11
Aurora Cannabis Inc
INVESTMENTS & OTHER ASSETS
Reverse stock split, ratio	12
Aurora Cannabis Inc \| Warrants
INVESTMENTS & OTHER ASSETS
Shares represented by warrants \| shares	81,164	973,971
Term of the warrant		5 years
Exercise price	$ 112.44	$ 9.37

FAIR VALUE MEASUREMENTS AND S_3

FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS - Recurring (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)$ / shares	Dec. 31, 2020USD ($)
Money Market Funds
Assets
Net Asset Value \| $ / shares	$ 1
Warrants
Assets
Equity Securities, FV-NI, Measurement Input	92	137
Equity Securities, FV-NI, Measurement Input [Extensible List]	Volatility	Volatility
Input increase (decrease) assumption, as a percent	20.00%	20.00%
Estimated change in fair value due to change in input	$ 6	$ 115
Fair Value, Recurring \| Short-term investments securities
Assets
Assets at fair value	47,400	21,313
Fair Value, Recurring \| Money Market Funds
Assets
Assets at fair value	8,919	8,636
Fair Value, Recurring \| Corporate Bonds
Assets
Assets at fair value	38,481	12,677
Fair Value, Recurring \| Warrants
Assets
Assets at fair value	5	239
Fair Value, Recurring \| Common Stock
Assets
Assets at fair value	2,340
Fair Value, Recurring \| Convertible note receivable
Assets
Assets at fair value		5,876
Fair Value, Recurring \| Preferred stock
Assets
Assets at fair value		5,173
Fair Value, Recurring \| Fair Value, Inputs, Level 1 \| Short-term investments securities
Assets
Assets at fair value	8,919	8,636
Fair Value, Recurring \| Fair Value, Inputs, Level 1 \| Money Market Funds
Assets
Assets at fair value	8,919	8,636
Fair Value, Recurring \| Fair Value, Inputs, Level 1 \| Corporate Bonds
Assets
Assets at fair value	0
Fair Value, Recurring \| Fair Value, Inputs, Level 1 \| Common Stock
Assets
Assets at fair value	2,340
Fair Value, Recurring \| Fair Value, Inputs, Level 2 \| Short-term investments securities
Assets
Assets at fair value	38,481	12,677
Fair Value, Recurring \| Fair Value, Inputs, Level 2 \| Money Market Funds
Assets
Assets at fair value	0
Fair Value, Recurring \| Fair Value, Inputs, Level 2 \| Corporate Bonds
Assets
Assets at fair value	38,481	12,677
Fair Value, Recurring \| Fair Value, Inputs, Level 3 \| Short-term investments securities
Assets
Assets at fair value	0
Fair Value, Recurring \| Fair Value, Inputs, Level 3 \| Money Market Funds
Assets
Assets at fair value	0
Fair Value, Recurring \| Fair Value, Inputs, Level 3 \| Corporate Bonds
Assets
Assets at fair value	0
Fair Value, Recurring \| Fair Value, Inputs, Level 3 \| Warrants
Assets
Assets at fair value	$ 5	239
Fair Value, Recurring \| Fair Value, Inputs, Level 3 \| Convertible note receivable
Assets
Assets at fair value		5,876
Fair Value, Recurring \| Fair Value, Inputs, Level 3 \| Preferred stock
Assets
Assets at fair value		$ 5,173

FAIR VALUE MEASUREMENTS AND S_4

FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS - Changes in fair value, Level 3 (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS
Fair value at beginning of the period	$ 11,288	$ 11,127
Unrealized loss as a result of change in fair value	(233)	(434)
Accretion of interest on note	142	595
Panacea investment conversion	(11,192)
Fair value at end of the period	$ 5	$ 11,288

FAIR VALUE MEASUREMENTS AND S_5

FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS - Available-for-sale debt securities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS
Available-for-sale Securities - Amortized Cost Basis	$ 38,643	$ 23,652
Available-for-sale Securities - Gross Unrealized Gains		74
Available-for-sale Securities - Fair Value	38,481	23,726
Corporate Bonds
FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS
Available-for-sale Securities - Amortized Cost Basis	38,643	12,603
Available-for-sale Securities - Gross Unrealized Gains	1	74
Available-for-sale Securities - Gross Unrealized Losses	(163)
Available-for-sale Securities - Fair Value	$ 38,481	12,677
Convertible note receivable
FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS
Available-for-sale Securities - Amortized Cost Basis		5,876
Available-for-sale Securities - Fair Value		5,876
Preferred stock
FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS
Available-for-sale Securities - Amortized Cost Basis		5,173
Available-for-sale Securities - Fair Value		$ 5,173

FAIR VALUE MEASUREMENTS AND S_6

FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS - Maturity of available-for-sale securities by contractual maturity (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
FAIR VALUE MEASUREMENTS AND SHORT-TERM INVESTMENTS
Available For Sale, Maturities One Year or Less, Amortized Cost	$ 8,286	$ 11,692
Available For Sale, Maturities One Through Five Years, Amortized Cost	30,357	11,960
Available for sale securities, amortized cost, total	38,643	23,652
Available For Sale, Maturities One Year or Less, Fair Value	8,280	11,753
Available For Sale, Maturities One Through Five Years, Fair Value	30,201	11,973
Available For Sale Securities, Fair Value	$ 38,481	$ 23,726

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) $ in Thousands	Nov. 30, 2021USD ($)	Jun. 30, 2020USD ($)	May 01, 2020USD ($)	Oct. 22, 2018USD ($)item	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jun. 22, 2018USD ($)
NOTES PAYABLE
Proceeds from payment protection program			$ 1,200
Directors And Officers insurance, policy term					1 year	1 year
Annual premium					$ 3,315	$ 2,744
Premium paid					662	549
Proceeds from Notes Payable					$ 2,653	$ 2,195	$ 2,653	$ 2,195
Debt Instrument, Term					9 months	9 months
Debt Instrument, Interest Rate, Stated Percentage		3.19%			3.49%	3.19%
License Fees								293
D&O Insurance							596	246
Total current notes payable							596	539
License Agreement \| North Carolina State University
NOTES PAYABLE
Aggregate milestone payments										$ 1,200
Notes Payable										1,175
Annual milestone payments beyond upfront amount		$ 300
Finite-Lived Intangible Assets, Gross										$ 1,175
License Agreement \| University Of Kentucky
NOTES PAYABLE
Aggregate milestone payments				$ 1,200
Notes Payable							1,151
Annual milestone payments beyond upfront amount	$ 300			300
License acquired				1,151
Upfront payment				$ 300
Number of installments \| item				3
Borrowings
NOTES PAYABLE
Accretion of non cash interest expense							$ 7	$ 20	$ 36

SEVERANCE LIABILITY (Details)

SEVERANCE LIABILITY (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
SEVERANCE LIABILITY (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020
SEVERANCE LIABILITY
Severance expense	$ 306	$ 881
Severance accrual		$ 771
Severance period	12 months	42 months
Accrued severance			$ 217	$ 339
Accrued severance, noncurrent			$ 21	$ 241

CAPITAL RAISE AND WARRANTS FO_3

CAPITAL RAISE AND WARRANTS FOR COMMON STOCK - Capital raise (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 07, 2021	Jul. 25, 2019	Jul. 22, 2019	Dec. 31, 2021	Dec. 03, 2019
CAPITAL RAISE AND WARRANTS FOR COMMON STOCK
Stock issued in connection with capital raise (in shares)	10,000,000	990,000	990,000
Share Price	$ 4				$ 1
Stock issued in connection with capital raise	$ 38,206			$ 38,206

CAPITAL RAISE AND WARRANTS FO_4

CAPITAL RAISE AND WARRANTS FOR COMMON STOCK (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 22, 2019	Nov. 25, 2019	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2019
CAPITAL RAISE AND WARRANTS FOR COMMON STOCK
Number of warrants exercised			(11,293,211)	11,293,211	11,293,211
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.11
Proceeds from Warrant Exercises			$ 11,782	$ 11,782	$ 10,616
Warrants Consecutive Trading Days	10 days
Warrants Weighted Average Price	$ 3
Warrant notice price (in dollars per share)	0.001
Exercise price	$ 1.11
New Warrants
CAPITAL RAISE AND WARRANTS FOR COMMON STOCK
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		11,293,211
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Exercised For Cash		7,350,000
Class of Warrant or Right, Cash Exercise Price of Warrants or Rights		$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Remaining		3,943,211
Proceeds from Warrant Exercises		$ 7,400			$ 10,600
Shares represented by warrants		11,293,211
Exercise price		$ 2.15
2019 Warrants
CAPITAL RAISE AND WARRANTS FOR COMMON STOCK
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 1.25
Initial exercise period				5 years
Exercise price					$ 1.25

CAPITAL RAISE AND WARRANTS FO_5

CAPITAL RAISE AND WARRANTS FOR COMMON STOCK - Warrants (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2019
CAPITAL RAISE AND WARRANTS FOR COMMON STOCK
Net proceeds from warrant exercises	$ 11,782	$ 11,782	$ 10,616
Warrant outstanding beginning balance	11,293,211	11,293,211	11,293,211
Exercised	11,293,211	(11,293,211)	(11,293,211)
Issued			11,293,211
Warrant outstanding ending balance		0	11,293,211

RETIREMENT PLAN (Details)

RETIREMENT PLAN (Details) - USD ($) $ in Thousands	12 Months Ended
RETIREMENT PLAN (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
RETIREMENT PLAN
Employer match of employee contribution, as a percent	3.00%
Employer contribution	$ 171	$ 150	$ 157

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Licenses (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Future Commitments
2022	$ 2,893
2023	2,118
2024	1,337
2025	1,374
2026 & After	2,730
Contractual Obligation, Total	10,452
Research Agreement \| KeyGene
Future Commitments
2022	1,150
2023	1,200
2024	1,227
2025	1,264
2026 & After	1,630
Contractual Obligation, Total	$ 6,471
Agreement Term	5 years
Agreement extension period	2 years
License Agreement \| Annual Royalty
Future Commitments
2022	$ 225
Contractual Obligation, Total	225
License Agreement \| Minimum Annual Royalty 1
Future Commitments
2022	50
2023	50
2024	50
2025	50
2026 & After	550
Contractual Obligation, Total	750
License Agreement \| Minimum Annual Royalty 2
Future Commitments
2022	50
2023	50
2024	50
2025	50
2026 & After	450
Contractual Obligation, Total	650
Sublicense Agreement With Anandia
Future Commitments
2022	10
2023	10
2024	10
2025	10
2026 & After	100
Contractual Obligation, Total	140
Growing Agreements
Future Commitments
2022	38
Contractual Obligation, Total	38
Consulting Agreements
Future Commitments
2022	1,370
2023	808
Contractual Obligation, Total	$ 2,178

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - MRTP, litigation (Details) $ in Thousands	Jun. 07, 2021shares	Jul. 25, 2019shares	Jul. 22, 2019shares	Jun. 30, 2019USD ($)	Jan. 15, 2020item	Nov. 19, 2019item
COMMITMENTS AND CONTINGENCIES
Number of shares issued in settlement \| shares	10,000,000	990,000	990,000
Voting period for shares awarded in settlement			5 years
Fair value of shares awarded in settlement \| $				$ 1,891
Number of counts \| item					3	3

LOSS PER COMMON SHARE (Details)

LOSS PER COMMON SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
LOSS PER COMMON SHARE
Net loss	$ (32,609)	$ (19,711)	$ (26,558)
Weighted average common shares outstanding - basic	156,208	138,813	125,883
Weighted average common shares outstanding - diluted	156,208	138,813	125,883
Net loss per common share - basic	$ (0.21)	$ (0.14)	$ (0.21)
Net loss per common share - diluted	$ (0.21)	$ (0.14)	$ (0.21)

LOSS PER COMMON SHARE - Anti-di

LOSS PER COMMON SHARE - Anti-dilutive securities (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
EARNINGS PER COMMON SHARE
Securities outstanding but excluded from computation of earnings per share	8,336	20,812	20,081
Warrants
EARNINGS PER COMMON SHARE
Securities outstanding but excluded from computation of earnings per share		11,293	11,293
Options
EARNINGS PER COMMON SHARE
Securities outstanding but excluded from computation of earnings per share	5,171	6,581	7,837
Restricted stock units
EARNINGS PER COMMON SHARE
Securities outstanding but excluded from computation of earnings per share	3,165	2,938	951

EQUITY-BASED COMPENSATION (Deta

EQUITY-BASED COMPENSATION (Details)	12 Months Ended
EQUITY-BASED COMPENSATION (Details)	Dec. 31, 2021shares
EQUITY- BASED COMPENSATION
Additional shares authorized during the period	5,000,000
Plan term	10 years
Number of shares remaining for future awards	7,526,630

EQUITY- BASED COMPENSATION - RS

EQUITY- BASED COMPENSATION - RSUs (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
RSUs, Number of shares
Nonvested, Number, Beginning Balance	2,938	951
RSUs granted, number	2,200	2,885	1,301
RSUs vested, number	(1,660)	(325)	(100)
RSUs forfeited, number	(313)	(573)	(250)
Nonvested, Number, Ending Balance	3,165	2,938	951
RSUs, Weighted average grant-date fair value
Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance	$ 0.85	$ 2.15
RSUs granted, grant-date fair value	3.25	0.71	$ 2.21
RSUs vested, grant-date fair value	0.85	1.07	2.02
RSUs forfeited, grant-date fair value	1.04	1.90	2.02
Nonvested, Weighted Average Grant Date Fair Value, Ending Balance	$ 2.50	$ 0.85	$ 2.15
Fair value of RSUs that vested during the period	$ 5,262	$ 601

EQUITY- BASED COMPENSATION - St

EQUITY- BASED COMPENSATION - Stock option activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of Options
Options, number, Beginning of Period	6,581	7,837	8,672
Options granted, number	235		600
Options exercised, number	(984)	(399)	(75)
Options forfeited, number	(600)	(169)	(1,360)
Options expired, number	(61)	(688)
Options, number, End of Period	5,171	6,581	7,837
Options exercisable, number, End of Period	4,836
Options, Weighted Average Exercise Price
Options, Beginning of Period, weighted average exercise price	$ 1.50	$ 1.49	$ 1.54
Options granted, weighted average exercise price	3.10		2.07
Options exercised, weighted average exercise price	1.37	1.04	0.93
Options forfeited, weighted average exercise price	1	1.83	2.09
Options expired, weighted average exercise price	2.64	1.51
Options, End of Period, weighted average exercise price	1.65	$ 1.50	$ 1.49
Options exercisable, End of Period, weighted average exercise price	$ 1.56
Weighted Average Remaining Contractual Term
Options, End of Period, weighted average remaining contractual term	3 years 7 months 6 days
Options exercisable, End of Period, weighted average remaining contractual term	3 years 4 months 24 days
Aggregate Intrinsic Value
Options, End of Period, aggregate intrinsic value	$ 7,431
Options exercisable, End of Period, aggregated intrinsic value	$ 7,375

EQUITY BASED COMPENSATION - Fai

EQUITY BASED COMPENSATION - Fair value assumptions (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2019
EQUITY- BASED COMPENSATION
Risk-free interest rate (weighted average)	0.54%	1.54%
Expected stock price volatility	87.92%	70.00%
Expected life of options (weighted average)	4 years 1 month 2 days	5 years 1 month 24 days

EQUITY-BASED COMPENSATION - Com

EQUITY-BASED COMPENSATION - Compensation expense and unrecognized compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
EQUITY BASED COMPENSATION
Equity-based employee compensation expense	$ 3,983	$ 1,654	$ 3,540
Unrecognized compensation	$ 4,685
Unrecognized compensation, period for recognition	9 months 18 days
Unrecognized compensation, options with milestone-based vesting	$ 517
Sales, general, and administrative
EQUITY BASED COMPENSATION
Equity-based employee compensation expense	3,821	1,526	3,166
Research and Development
EQUITY BASED COMPENSATION
Equity-based employee compensation expense	$ 162	$ 128	$ 374

INCOME TAXES - Provision (Detai

INCOME TAXES - Provision (Details) - USD ($) $ in Thousands	12 Months Ended
INCOME TAXES - Provision (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred:
Federal	$ (7,566)	$ (3,932)	$ (5,607)
State	(1)	(200)	55
Total deferred	(7,567)	(4,132)	(5,552)
Change in valuation allowance	7,581	4,170	$ 5,552
Income Tax Expense (Benefit), Total	$ 14	$ 38

INCOME TAXES - Rate reconciliat

INCOME TAXES - Rate reconciliation (Details)	12 Months Ended
INCOME TAXES - Rate reconciliation (Details)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
INCOME TAXES
Statutory federal rate	(21.00%)	(21.00%)	(21.00%)
Other items	0.50%	(0.30%)	(0.10%)
Litigation Settlement			1.50%
Stock based compensation	(2.70%)	0.70%	1.80%
Research and development credit carryforward	(0.10%)	0.20%	(3.30%)
State tax provision, net of federal benefit		(0.80%)	0.20%
Valuation allowance	23.30%	21.40%	20.90%
Effective tax rate (benefit) provision		0.20%

INCOME TAXES - Deferred Tax Ass

INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss carry-forward	$ 24,859	$ 18,498	$ 14,996
Inventory	104	115	52
Stock-based compensation	1,326	1,099	1,049
Start-up expenditures	177	199	221
Research and development credit carryforward	1,192	1,171	1,209
Accrued bonus	411	423	200
Severance liability	50	122	134
Unrealized loss on investments	1,366	371	40
Operating lease obligations	365	52	127
Capital loss on investment	107
Other	18	18	22
Total deferred tax assets	29,975	22,068	18,050
Deferred tax liabilities:
Machinery and equipment	(254)	(237)	(239)
Patents and trademarks	(373)	(358)	(351)
Gain on investment		(13)	(104)
Accrued expense		(24)	(51)
Operating lease right-of-use assets	(362)	(52)	(126)
Other intangible assets	(259)	(224)	(189)
Total deferred tax liabilities	(1,248)	(908)	(1,060)
Valuation allowance	(28,779)	(21,198)	$ (16,990)
Net deferred taxes	$ (52)	$ (38)

INCOME TAXES - NOLs, Unrecogniz

INCOME TAXES - NOLs, Unrecognized (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017
INCOME TAXES
Net operating loss carryforward	$ 70,658,000
Accumulated an net operating loss carryforward				$ 46,920,000
Research and development credit carryforward	1,192,000	$ 1,171,000	$ 1,209,000
Capital loss carryover	510,000
Liability for uncertain tax positions	$ 0

REVENUE RECOGNITION (Details)

REVENUE RECOGNITION (Details) $ in Thousands	12 Months Ended
REVENUE RECOGNITION (Details) $ in Thousands	Dec. 31, 2021USD ($)customer	Dec. 31, 2020USD ($)customer	Dec. 31, 2019USD ($)customer
REVENUE RECOGNITION
Allowance for discounts or returns and allowances	$ 0	$ 0
Payment period	21 days
Unbilled receivables	$ 178	349
Deferred revenue	(119)	(272)
Net contract assets	59	77
Total Revenue	$ 30,948	$ 28,111	$ 25,833
Number of customers \| customer	3	2	3
Excise taxes	$ 10,135	$ 9,859	$ 9,187
Net sales-over time
REVENUE RECOGNITION
Total Revenue	21,061	16,326	16,466
Net sales-point in time
REVENUE RECOGNITION
Total Revenue	$ 9,887	$ 11,785	$ 9,367
Revenue
REVENUE RECOGNITION
Risk concentration, as a percent	84.00%	91.00%	93.00%

SUBSEQUENT EVENT (Details)

SUBSEQUENT EVENT (Details) £ / shares in Units, £ in Thousands, $ in Thousands	Dec. 10, 2021GBP (£)£ / sharesshares	Jun. 07, 2021USD ($)	Dec. 31, 2021USD ($)	Jan. 26, 2022USD ($)	Jan. 26, 2022GBP (£)	Dec. 31, 2020USD ($)
Subsequent Event [Line Items]
Investments			$ 2,345			$ 6,536
Minimum total of equity investments		$ 38,206	38,206
Minimum amount of equity investments			$ 38,206
Change Agronomy Ltd
Subsequent Event [Line Items]
Investments \| £	£ 500
Minimum \| Change Agronomy Ltd
Subsequent Event [Line Items]
Minimum total of equity investments \| £	£ 3,000
Change Agronomy Ltd
Subsequent Event [Line Items]
Number of ordinary shares \| shares	592,888
Number of ordinary price per share \| £ / shares	£ 0.84333
Subsequent Event \| Change Agronomy Ltd
Subsequent Event [Line Items]
Investments				$ 682	£ 500
Ownership percentage (in percent)				1.80%	1.80%

SCHEDULE II-VALUATION AND QUA_2

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Valuation allowance on net deferred tax assets
Valuation Allowances and Reserves
Balance at beginning of period	$ 21,198	$ 16,990	$ 11,438
Charged to costs and expense	7,581	4,208	5,552
Balance at end of period	28,779	21,198	16,990
Allowance for slow moving or obsolete inventory
Valuation Allowances and Reserves
Balance at beginning of period	100	100	100
Charged to costs and expense	317	521	985
Deductions	(317)	(521)	(985)
Balance at end of period	$ 100	$ 100	$ 100